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 Nicotine addiction, opioid use disorder, and COVID-19 have made lasting 
impacts on every aspect of society. These are complicated conditions, and studies 
in these fields will likely continue for decades, if not centuries. Here, we make 
contributions to each of these issues using electrophysiology and microscopy. The 
first chapter goes into the motivation behind this thesis and the major experiments 
I used in my graduate career. In the second chapter, we introduce a new amino 
acid into the mouse muscle nicotinic acetylcholine receptor in an attempt to 
understand the dynamics of receptor activation. In the third chapter, we continue 
the Lester lab’s work on the neuroscientific effects of menthol and how it plays a 
role in nicotine addiction. We found the binding site for menthol on the α4β2 
nicotinic acetylcholine receptor, which continues our hypothesis that the 
neuroscientific effects of menthol are detrimental to cigarette smokers. 
Fortunately, partly because of our studies, mentholated nicotine products are being 
phased out of the United States. The fourth and fifth chapters investigate µ-opioid 
receptor trafficking, both the trafficking from the endoplasmic reticulum and 
endocytosis from the plasma membrane. Both of these events play a role in 
inducing opioid use disorder and increasing the danger of using opioids. We hope 
that these studies will help other researchers understand opioid use disorder and 
fight the opioid epidemic. Finally, we studied the effects of SARS-COV-2 proteins 
on epithelial sodium channels. These channels are important for regulating lung 
fluid levels where their improper function may cause pulmonary edema. Pulmonary 
edema has been observed in COVID-19 patients. Altogether, we believe that we 
have made meaningful impacts on these important health concerns in this thesis. 
We look forward to how the scientific communities continue to build on our results. 
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Chapter 1: Introduction 
1.1 The Nicotinic Acetylcholine Receptors and Allosteric Modulators 
Smoking is currently the leading cause of preventable death and costs the 
United States over $100 million in direct medical costs.1 The nicotinic acetylcholine 
receptors (nAChR) play a large role in nicotine addiction and other central nervous 
system (CNS) diseases like Parkinson’s and Alzheimer’s disease. The nAChRs 
are a family of pentameric ligand-gated ion channels responsible for some of the 
signaling at the neuromuscular junction by acetylcholine (ACh) or several 
exogenous ligands such as nicotine. Smoking tobacco or using electronic nicotine 
delivery systems (ENDS) will introduce exogenous nAChR agonists. Initial reports 
suggest that ENDS use is harmful to humans. There is a long history 
demonstrating that smoking causes harm to the cardiovascular system and is a 
leading cause of cancer.2-5 While anti-smoking campaigns have been very 
successful at preventing young adults from smoking conventional cigarettes, 
ENDS have recently made a major impact on the health of the youth as “vaping” 
is popular among high school students. We have witnessed an increase in nicotine 
consumption due to these products (Figure 1.1).6 
While a key factor in the addictive potential in ENDS and conventional 
cigarettes is nicotine, several other compounds influence the action of the 
nAChRs. One class of these molecules is the allosteric modulators. Allosteric 
modulators are different from agonists or antagonists in that allosteric modulators 
do not bind at the orthosteric site. For the neuronal nAChRs, the orthosteric site is 
at the α-β or α-α interface. It is characterized by an aromatic box which allows for 
an important cation-π interaction to form.7,8 However, allosteric  modulators will 
bind to another location, and its binding will affect the energy landscape of the 
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nAChR (Figure 1.2). Positive allosteric modulators (PAMs) will shift the energy  
landscape to increase the stability of the active conformation, increase agonist 
affinity (shift the EC50 for an agonist to a lower concentration), or increase the 
maximal current elicited by the receptor. A negative allosteric modulator (NAM) will 
increase the stability of an inactive conformation, decrease agonist affinity (shift 
the EC50 for an agonist to a higher concentration), or reduce the maximal current 
elicited by the receptor. A neutral allosteric modulator will not affect agonist activity 
but may prevent other allosteric modulators from binding to that allosteric site. 
Nevertheless, just because two molecules are allosteric modulators does not mean 
they will bind to the same location. For example, the gamma-aminobutyric acid 
(GABA) receptor has more than one allosteric site.9 One should also note that just 
because a molecule binds at an allosteric site does not mean it is an allosteric 
modulator. Finally, certain compounds can act as both PAMs and NAMs 
depending on the concentration. One example is Zn2+, where the EC50 for 
Figure 1.1. High School student tobacco product consumption increased 




potentiation is 168 µM, but the IC50 for inhibition is 3.2 mM for the (α3)2(β4)3 
nAChR.10  
The α4β2 nAChR is especially important as it is the most prominent 
heteromeric subtype in the brain.11 The α4β2 nAChR can be found in two 
stoichiometries: the high-affinity (α4)2(β2)3 or the low-affinity (α4)3(β2)2 
stoichiometry. The high-affinity stoichiometry will bind to ACh with an EC50 of ~1 
µM, while the low-affinity stoichiometry will bind with an EC50 of ~ 83 µM.12 The 
α4β2 receptor provides one of the main binding sites for nicotine in the brain.13 
Picciotto et al. found that the high-affinity binding sites were absent from mice 
where the β2 subunit was mutated and their thalamic neurons did not respond to  
nicotine.14 Furthermore, the α4β2 nAChR has been implicated in perception, 
cognition, emotion, nicotine self-administration, reward, and dependence.15 
Clearly, α4β2 nAChR has a 
tremendous influence on a 
patient’s response to nicotine, 
and likewise, anything that 
affects the α4β2 nAChR may 
also affect a person’s 
susceptibility to nicotine 
addiction. 
 Unfortunately, recent 
work has shown that tobacco 
and ENDS flavorants are NAMs 
of the α4β2 nAChR.12,16 The 
most prominent of these 
Figure 1.2 How allosteric modulators effect 
EC50 curves by (A) changing the EC50 or (B) 
changing the maximal response 
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flavorants is menthol which is the only flavorant allowed in conventional cigarettes 
in the United States after the 2009 Family Smoking Prevention and Tobacco 
Control Act. However, due to our work and other studies demonstrating that flavors 
entice youth to start using nicotine products, flavorants are being phased out in 
many nicotine products. Already, Canada and San Francisco have banned the sale 
of menthol cigarettes. The popular ENDS manufacturer Juul has stopped 
producing many of its flavored oils to combat the spread of adolescent nicotine 
addiction. The third chapter of this thesis details my efforts on this issue.12   
1.2 The Opioid Receptors and Protein Trafficking 
The United States is currently facing an opioid abuse epidemic that is causing 
over 1000 emergency room visits and approximately 91 deaths every day (Figure 
1.3).17 Drug overdose is currently the leading cause of accidental death in the 
United States and opioids are the most common drug overdosed. The prevalence 
of opioids is largely a result of these compounds being exceptional treatments for 
Figure 1.3. The opioid epidemic has grown the past two decades (Comptom 2016). 
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pain.18 To this day, despite billions of dollars being spent looking for alternative 
pain medications, opioids remain the gold standard.19 With approximately 100 
million people suffering from some form of pain in the United States, opioids are 
among the most prescribed medications, having been dispensed 245 million times 
in 2014.18,19 Public policy has attempted to combat the epidemic by monitoring 
prescriptions. However, the lack of a better option has left healthcare providers 
with few options other than prescribing these addictive substances. Indeed, these 
opioids, which include buprenorphine, fentanyl, hydromorphone, methadone, 
morphine, and oxycodone, will also cause respiratory depression, leading to death 
if any of these opioids are taken in excess.  
The primary target for all of these opioids is the µ-opioid receptor (MOR). These 
receptors are expressed throughout the human body, but, consistent with its role 
in opioid use disorder, it is prominently expressed in the ventral tegmental area in 
the brain.20 On a system level, MOR activation leads to dopamine release into the 
nucleus accumbens, giving rise to a pleasurable sensation. The rest of the brain 
creates conditioned associations with this feeling and the opioid. This association 
between pleasure and opioids drives the initial compulsions for opioid use, but 
eventually, secondary responses build as the body becomes accustomed to the 
chronic presence of opioids. These secondary effects can be broken down into 
tolerance and dependence. Tolerance involves the escalating doses required to 
elicit a certain response. Dependence refers to the body’s need for the stimuli to 
function normally. When a patient that has developed dependence is taken off 
opioids, withdrawal symptoms occur. Both tolerance and dependence are induced 
with consistent opioid use and contribute to opioid use disorder.  
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 On a molecular level, MOR 
activation causes several 
responses in  neurons. First, the 
MORs are coupled to the Gi/o 
proteins.21 Upon activation, there is 
a decrease in the conversion of 
adenosine triphosphate (ATP) to 
cyclic adenosine monophosphate 
(cAMP), which leads to decreases 
in the release of noradrenaline; thus 
the subject experiences sedation 
and shallow breathing (Figure 
1.4).20 To combat this, the neuron 
will increase the intracellular 
concentration of adenyl cyclase, 
thus leading to an increase in 
[cAMP] and offsetting the effects of 
the opioids. Indeed, there are 
disadvantages to feeling drowsy, so 
humans are evolutionarily inclined 
to reverse these effects to some 
degree. When opioids are not 
present, these adjustments to 
adenyl cyclase expression cause 
the [cAMP] to be higher than normal and excessive amounts of noradrenaline to 
Figure 1.4. Overview of [cAMP] changes 
during (A) normal function, (B) upon initial 
opioid exposure, (C) upon development of 
tolerance, (D) during withdrawal. [cAMP] is 
directly related to noradrenaline release. 
(Kosten 2002)    
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be produced, inducing feelings of anxiety, muscle cramps, and diarrhea. 
Essentially, one experiences withdrawal and these effects are abolished with time, 
but a subject can take more of the opioid to remove the withdrawal symptoms. 
Unfortunately, since tolerance is induced with dependence, the dose required to 
reverse withdrawal symptoms increases. Furthermore, with the escalating 
dosages, many subjects suffering from opioid use disorder eventually take a dose 
that causes severe respiratory depression (due to the large drop of noradrenaline) 
and death. 
 Several diseases can result from deficiencies in protein trafficking. The 
2013 Nobel Prize in Physiology or Medicine went to James Rothman, Randy 
Figure 1.5. Overview of membrane protein trafficking with an expanded view of  
the COPII vesicle (Henderson 2015). 
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Schekman, and Thomas Südhof “for their discoveries of machinery regulating 
vesicle traffic, a major transport system in our cells.”22 In general, most membrane 
proteins will be translated by ribosomes and mature in the endoplasmic reticulum 
(ER). Proper folding will result in forming an endoplasmic reticulum exit site 
(ERES) that will guide the protein to the Golgi for further processing before finally 
being trafficked to the plasma membrane.  
 ERES formation has been studied extensively (Figure 1.5).23-26 First, 
Sar1p, a Ras-like GTPase, phosphorylates GDP, and associates with the ER. This 
process leads to membrane curvature that will eventually generate a vesicle and 
detach from the rest of the ER.27 Sar1p then recruits Sec23/Sec24 heterodimers, 
constituting the inner coat of ERES. Sec24 is also responsible for cargo binding. 
The four Sec24 subtypes (designated A-D) have unique binding motifs, and there 
have been reports that cargo can bind to one, two, three, or all four of these 
subtypes.28-31 Then, the Sec13/Sec31 heterodimer is recruited to form the outer 
coat. Then, GTP hydrolysis by Sar1p causes the components to dissociate from 
the ER, and the entire complex and cargo will transport to the Golgi. Based on 
some calculations performed by Heinzer et al., 48 COPII complexes make up a 
COPII vesicle, and about 12 COPII vesicles make up a single ERES.32 Within a 
mammalian cell, there can be hundreds of ERES, each with a diameter of 
approximately 500 nm.   
 The ERES are of particular interest to the Lester lab. Prior group members 
have found that nicotine’s ability to increase the membrane density of α4β2 
nAChRs occurs through an ERES-dependent process.33 By using fluorescently 
tagged Sec24 proteins and confocal microscopy, the Lester lab observed 
increases in the number of ERES in cells overexpressing α4 and α6 nAChRs when 
9 
 
the cells are treated with nicotine. The hypothesis to explain these observations is 
that nicotine serves as a pharmacological chaperone for these nAChRs.34 
Essentially, because nicotine will cross the plasma membrane, nicotine can target 
nAChRs in the cytoplasm. This includes the ER when the nAChRs are folded and 
assembled.34 We believe that these ligands bind to the α4-containing (α4*) and α6-
containing (α6*) nAChRs to promote a trafficking-enabled conformation, thus 
biasing them to the Golgi through ERES-mediated transport.  
 This thesis's fourth chapter will delve into how we applied these ideas to 
the opioid receptors and how antagonists pharmacologically chaperone the 
receptors to the plasma membrane. Much like the relationship between nicotine 
and nAChRs, naltrexone and naloxone will increase the surface density of the 
MOR.35-38 While these papers hypothesize that pharmacological chaperoning is 
the mechanism, no direct intracellular experiments have been done to confirm 
these ideas. Expanding on the experiments of previous lab members, I do 3D 
image analysis to suggest that the opioid receptors are being chaperoned by the 
antagonists naltrexone (Ntx) and naloxone, but not agonists or allosteric 
modulators. I also show that this chaperoning event is dependent on the 
antagonists entering the cell. This discovery introduces a new way to approach the 
opioid epidemic by using “inside-out” pharmacology. 
In terms of its localization in the cell, the MOR predominately localizes to the 
plasma membrane.39 This contrasts with the δ- and κ-opioid receptors, which 
primarily localize within the cytoplasm.40 Regulation of the surface density of the 
MOR has received tremendous attention because certain agonists, like fentanyl 
and the synthetic peptide DAMGO, will cause endocytosis of the MOR.41 Morphine, 
on the other hand, has been shown to have different effects on MOR endocytosis 
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depending on the system used.42,43 Along with the morphine story, what role 
agonist-induced MOR endocytosis has on opioid use disorder is hotly contested.44-
46 On the one hand, MOR endocytosis will diminish the available pool of receptors 
activated on the surface, so endocytosis is desired. On the other hand, studies 
have shown that endocytosis is followed by receptor recycling.47 Endocytosis may 
be a mechanism for removing desensitized receptors and allowing them to 
resensitize through recycling. In this sense, if desensitization occurs in the 
absence of endocytosis and subsequent recycling, endocytosis is not desired. 
However, resensitization in the absence of recycling has also been observed.48 
There are studies where MOR activation has been observed at an intracellular site, 
so the importance of these intracellular activation events must be considered.49 
Ultimately, the trafficking of the MOR and its role in opioid use disorder is not 
completely understood. 
 In the fifth chapter, we conduct novel experiments investigating C-terminal 
phosphorylation's role on morphine- and fentanyl-induced endocytosis. Using a 
fluorescently tagged MOR and visualizing early endosomes with CellLightTM Early 
Endosome GFP, we can calculate the Pearson's correlation coefficient as a 
measure of MOR endocytosis. Our initial experiments demonstrate that in our 
system, both morphine and fentanyl will increase MOR endocytosis. However, we 
do not observe a significant increase in morphine-induced endocytosis in any 
receptor where the S375 residue is mutated to alanine. The S375 residue has been 
established as an important phosphorylation site, and our experiments are 
consistent with this hypothesis.50-53 We could only prevent fentanyl-induced MOR 
endocytosis if we mutated T354, S355, S356, T357, S363, S364, T370, S375, 
T376, and T379 to alanine. These results suggest that C-terminal phosphorylation 
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is an important step to MOR endocytosis, and these particular residues are of 
special interest. 
1.3 Epithelial sodium channels’ role in COVID-19 
 For decades, we have that known species crossover events of diseases 
present major public health threats.54 In December 2019, the first instance of 
SARS-CoV-2 infection in a human was documented. In roughly four months, a 
pandemic was declared, and millions of lives have been lost since. Fortunately, 
the global scientific community mobilized to learn more about this disease and find 
treatments. Nonetheless, it is unlikely that this will be the last crossover event, and 
it is important to continue to study SARS-CoV-2 to understand how to track and 
treat other pandemic-causing agents. 
The symptoms of COVID-19 include severe respiratory distress that can 
lead to death. A specific form of respiratory distress is pulmonary edema, which 
has been observed in COVID-19 patients.55 Pulmonary edema results from 
improper fluid regulation in the respiratory system, which may originate from 
malfunctioning epithelial sodium channels (ENaC).56 ENaCs are partly responsible 
for regulating fluid levels because the flow of sodium ions will coincide with water 
flow via osmosis. If these channels do not function properly, then serious 
complications can develop, many of which have been observed in COVID-19 
patients.  
These symptoms were also observed in SARS patients, which is the 
disease caused by SARS-CoV-1. SARS-CoV-1 and SARS-CoV-2 are related 
beta-coronaviruses with many homologous proteins.57 In 2009, Ji and co-workers 
explored how some of the SARS-CoV-1 proteins influenced ENaC activity.58 Ji and 
co-workers found that SARS-CoV-1 spike (S) and envelope (E) protein decreased 
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ENaC activity in Xenopus oocytes. Ultimately, they found that this was a result of 
protein kinase C activation by these SARS-CoV-1 proteins. 
Chapter six documents our efforts to investigate how SARS-CoV-2 E and 
S proteins affect ENaC activity. Although there is 96% and 76% sequence identity 
between the two SARS virus E and S proteins, respectively, there is still merit in 
measuring these potential effects. Indeed, while SARS and COVID-19 are similar 
diseases, they have significant differences in how humans and communities were 
affected by the diseases. Here, we find that the effects of the E protein are 
conserved, and, in our hands, inhibition was only observed for SARS-CoV-2 S 
protein, but not SARS-CoV-1 S protein. We believe this difference results from 
using different controls; Ji and co-workers compared their results to oocytes 
injected with ENaC mRNA only. We compared our results to oocytes injected with 
ENaC and a control mRNA (SARS-CoV-2 ORF8), which does not interact with 
ENaC. We believe that SARS-CoV-1 S protein appears to decrease ENaC 
currents in the Ji et al. experiments because the extra mRNA utilized translational 
resources in the oocyte that otherwise would have been used to generate more 
ENaC. We also found that the PKC inhibition experiments that could recover ENaC 
activity in the Ji et al. paper could not recover ENaC activity in our hands. Finally, 
we did some mechanistic work to look at one of the differences between the SARS-
CoV-1 and SARS-CoV-2 S proteins: the introduction of a furin-cleavage motif. We 
know that ENaC function, specifically ENaC-α, requires furin cleavage. Suppose 
SARS-CoV-2 S protein is taking some of the available furin. In that case, this will 
decrease the amount of ENaC-α being cleaved and thus reduce active ENaC 
levels.59 Here, we found that we could slightly recover ENaC activity by mutating 
this site. However, we did not observe complete recovery. Ultimately, these 
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findings are just one of many basic science discoveries that will help us fight the 
current and potential future pandemics.  
1.4 Major Experiments 
1.4.1 Two-electrode voltage-clamp electrophysiology on Xenopus oocytes 
The first electrophysiology experiment may be attributed to Luigi Galvani when 
he could cause a dead frog’s leg to twitch with electricity. Since that famous 
experiment, we now understand how important electricity is to virtually every 
aspect of life. Indeed, life relies on being able to manipulate energy, and a great 
deal of it is stored as potential energy in the form of a voltage gradient across 
various lipid membranes. Galvani was probably changing the potential in some of 
these dead frog neurons, which despite being dead, were still able to transmit that 
change in the potential to other neurons and muscle fibers and induce muscle 
contraction. Since then, popular literature and frontier science have been 
fascinated with electrophysiology and what we can learn about life by 
understanding it from an electrical perspective. 
While there are numerous ways to observe currents and potentials in a living 
system, the experiment I focused on during my graduate career was the two-
electrode voltage clamp (TEVC) technique. Each electrode is typically made from 
a glass pipette and closed off at a sharp point that will eventually be impaled into 
the sample. The electrode is filled with a solution with a high concentration of KCl, 
and when impaled into the sample, they can form a high resistance seal so that 
most of the fluctuations in voltage or current result from a physiological response. 
Two electrodes are necessary as one will be used to measure the potential across 
the membrane, and the other will inject current into the sample to maintain the 
potential at a set voltage; thus, the voltage across the membrane is “clamped.” 
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Using both of these electrodes with an appropriate rig and software will ultimately 
give a current reading across the membrane.  
One way people have used TEVC electrophysiology is to study ion channels. 
The idea behind these experiments is that ion channel opening will allow ions to 
flow through these channels down their electrical gradient when there is a set 
potential across the membrane. This movement of charge will create a current, 
and one can measure these currents with TEVC techniques. From here, many 
different experiments can be done to investigate the various properties of ion 
channels. One way is to perform voltage jump experiments where the clamped 
voltage changes and the changes in current are recorded. These experiments 
were done to identify the M2 protein, made by an influenza virus, as a viroporin.60 
Further work leveraging M2’s role as an ion channel lead to the development of 
the antiviral drugs amantadine and rimantadine.61 Indeed, Wang et al. observed 
channel block with amantadine, and this observation lead to further experiments 
with amantadine and the related rimantadine as antiviral drugs. Another method is 
to use ligands to change the open-state probability of the ion channel. This is most 
popularly done with ligand-gated ion channels (LGIC) like the nAChRs. Using 
TEVC, one can test a series of compounds to determine if they are agonists, 
antagonists, or allosteric modulators of these LGICs by determining whether the 
compound will open, prevent the opening, or modulate activation, respectively. 
One can also rank these compounds by how well they act on these LGICs. For 
example, if compound A at low doses can induce the same currents as compound 




Unfortunately, most mammalian cells are quite small and range between 10-
100 µm in diameter.62 From an experimental standpoint, it is possible to perform 
electrophysiology experiments on these cells, but it would be easier and faster to 
use a larger model, especially if one wants to use the TECV technique. 
Fortunately, the oocytes from the African frog species Xenopus laevis are quite 
ideal for these experiments. These oocytes are 1 mm in diameter, so one can 
easily impale them with the two electrodes. The oocytes also facilely assemble and 
traffic many membrane proteins to the plasma membrane, and their general lack 
of other ion channels makes them the perfect model system for most TEVC 
experiments.63 Transfection of these oocytes typically involves injecting mRNA into 
the oocyte, and owing to its large size, it is a fairly easy procedure, and the oocytes 
tolerate this technique well. Additionally, one can simultaneously express many 
different proteins in each oocyte, making protein-protein interaction or heteromeric 
ion channel work possible. 
In terms of nAChR research, the utility of the Xenopus oocyte and the TEVC 
technique is perfect for a range of questions. Since the nAChRs are a family of 
pentameric ion channels typically composed of different subunits, expressing 
several proteins is critical.64 Additionally, currents from the α7 receptor can be 
enhanced when a protein chaperone, like Ric-3 or NACHO, is expressed, so 
expressing multiple proteins is useful even when one subunit is desired.65,66 An 
additional benefit to injecting mRNA is that precise stoichiometries can be induced 
since transcription is done in vitro and translation efficiencies are easier to predict 
with direct mRNA injection than with more conventional transfection methods with 
cDNA. For example, fairly consistent expression of either (α4)2(β2)3 or (α4)3(β2)2 
can be achieved by modulating the ratio of α4:β2 mRNA injected into the oocyte.12 
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Alternatively, one can observe a mix of stoichiometries using the same method. 
Lastly, the α5 subunit is an accessory subunit meaning that it cannot form 
functional receptors without other α subunits.67,68 Therefore, any experiment with 
these channels will have to answer the question of how to differentiate between 
the α5* nAChRs from the non-α5* nAChRs. Fortunately, due to the ability to 
precisely control each subunit's expression, simply using a much larger ratio of α5 
mRNA (>10-fold more) will nearly ensure that all receptors will form with an α5 
subunit.67  
Due to the large surface area that allows for potentially high surface densities 
of ion channels coupled with a highly sensitive technique like TEVC 
electrophysiology, even poorly expressed receptors can be detected. This 
becomes especially relevant in the next section, which discusses non-canonical 
amino acid (NCAA) mutagenesis. 
 
1.4.2 NCAA mutagenesis 
There are twenty standard or canonical amino acids encoded by all organisms 
using the 64 possible codons, where three of these codons cause translation 
termination. Their side chains from the α-carbon characterize each amino acid, 
and the twenty canonical amino acids cover quite a variety of chemical moieties. 
However, for precise and extensive chemical biology experiments, these twenty 
residues are very limiting. At this point, chemical biologists have looked for ways 
to incorporate NCAAs to answer some of their questions. For example, in terms of 
phenyl groups, chemical biologists were limited to tyrosine or phenylalanine. While 
there are certainly NCAAs that can completely utilize the natural translation 
machinery, they are limited.69 At the moment, there are two popular methods for 
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incorporating NCAAs into proteins: the orthogonal tRNA/synthetase method and 
the in vitro tRNA aminoacylation method. 
The Schultz lab discovered the orthogonal tRNA/synthetase method in 2001.70 
Since then, chemical biologists have been pushing the boundaries of what is 
possible with proteins. Here, this group had to optimize the tRNA, the synthetase, 
and the NCAA. The synthetase had to charge the orthogonal tRNA with the NCAA 
selectively, and whatever proofreading mechanisms the organism has has to fail 
to recognize the NCAA as unnatural. Lastly, the NCAA could not be recognized by 
any of the endogenous synthetases or tRNAs. After a heroic effort, they were 
successful, and they generated a functional chloramphenicol acetyltransferase 
protein in Escherichia coli with an O-methyl-L-tyrosine incorporated at a specific 
location.70 Since then, many NCAAs have been successfully incorporated into 
proteins in bacterial and mammalian cells for experiments involving 
photocrosslinking, click chemistry, microscopy, and post-translational 
manipulation.71-77 
While the tRNA/synthetase method is incredibly useful, introducing novel 
NCAAs can be quite laborious and even impossible. Indeed, there is no guarantee 
that the NCAA one wants to use will not be recognized by endogenous 
synthetases, which will make a selective modification of a single residue quite 
difficult. To eliminate this barrier, one could charge the tRNA in vitro (Figure 1.6). 
This is the essence behind the second NCAA incorporation technique, in which, 
through chemical synthesis and in vitro transcription, the NCAA and tRNA can be 
facilely coupled.78 Generally, the NCAA is made with a  dinucleotide on the 
carboxyl group (for efficient coupling to the rest of the tRNA) and a protecting group 
on the amine (to prevent the amine from hydrolyzing the tRNA). After the NCAA  
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has been charged onto the tRNA, the protecting group is removed, and it is ready  
to participate in translation at the appropriate codon designated by the tRNA’s 
anticodon. Thus, in bypassing the amino acid selection stage of tRNA charging, 
even very small modifications to a canonical amino acid can be efficiently and 
selectively incorporated at a site of interest. One example is adding fluorine  
substituents in place of hydrogens. This is a fairly minor change in steric bulk, and 
it is unlikely that a phenylalanine residue decorated with fluorine will be 
distinguishable from native phenylalanine by the endogenous synthetases. 
However, by simply omitting phenylalanine from the reaction mixture, the tRNA will 
only be charged with whatever NCAA is in the reaction vessel. One could not do 
the same with the orthogonal tRNA/synthetase method because phenylalanine is 
Figure 1.6 Overview of the TECV and in vitro aminoacylation technique in Xenopus 
oocytes (Dougherty 2014). 
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an essential amino acid, and substituting fluoro-phenylalanine in the media will 
cause all phenylalanine residues to be fluoro-phenylalanine, and the selectivity 
component is lost. Ultimately, if one very small modification is desired at just one 
residue, the in vitro aminoacylation method is superior to the orthogonal 
tRNA/synthetase method.      
One of the main issues with the in vitro aminoacylation method is that, even 
under ideal circumstances, it requires stoichiometric amounts of tRNA-NCAA since 
the living system cannot charge the tRNA on its own.78 Further, translation with the 
exogenously supplied tRNA-NCAA will not be perfect and some fraction of it will 
become uncharged, thus a greater than stoichiometric amount of material will be 
needed. However, TEVC electrophysiology is an incredibly sensitive technique in 
that <10 attomoles of functional protein are detectable on the oocyte surface.78 
This is well within reach of the in vitro aminoacylation technique, and this has 
allowed atomic level precision to be attained in experiments studying ion 
channels.1,8,12,67,78-82  
In this thesis, we use this method extensively in Chapter Two in our attempts 
to incorporate a solvatochromic amino acid into the mouse muscle nAChR. The 
idea for the second chapter was to visualize protein conformation changes in real 
time using microscopy. While structural data on the nAChRs have been 
tremendously useful, they are ultimately just an image of the nAChR at a single 
time point. By observing changes in the fluorescent properties of a solvatochromic 
amino acid in a nAChR, we will understand when that residue and region of the 
protein enters a more hydrophobic or hydrophilic environment. Furthermore, this 
technique is used in the third chapter of this thesis to probe potential hydrogen 
bonding interactions between menthol and the α4β2 nAChR.  
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1.4.3 ERES monitoring in SH-SY5Y cells 
Here, we became interested in membrane protein trafficking, much in line with 
the intracellular effects of menthol and nicotine on α4* nAChRs prior Lester lab 
members had found.83 Our strategy centers around using fluorescently tagged 
Sec24 proteins to observe ERES under different conditions. Specifically, with our 
library of opioid agonists and antagonists, we were interested in how opioid 
receptors responded to these ligands. We already know that the surface density 
of opioid receptors increases with antagonists and decreases with some agonists, 
but intracellular examination has not been done yet.36,43,84-88 
While 
Henderson et al. 
and Srinivasan et 
al. did great work 
with ERES 
experiments, my 
projects sought to 
expand on these 
techniques.83,89 The 
four most significant improvements in our experiments are: 1) we used human cells 
instead of mouse cells, 2) we analyzed 3D information after obtaining z-stacks, 3) 
we improved optical resolution by using a better microscope, and 4) we used 
objective as opposed to subjective thresholds for ERES designation. While 
switching cell lines on the surface is simple, Henderson et al. and Srinivasan et al. 
used neuro-2a cells because a transfection method with Lipofectamine 2000 had 
been optimized. Here, I optimized the transfection of a human neuroblastoma cell 
Figure 1.7. Basic schematic of the difference in image 
collection from conventional confocal microscopy and 
Airyscan microscopy (Korobchevskaya 2017) 
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line, the SH-SY5Y cells, with Lipofectamine 3000. Points two and three are related 
as z-stacks were only possible because we transitioned from a several decades-
old Nikon microscope to a state-of-the-art Zeiss LSM 880 with a Fast Airyscan 
module (Figure 1.7).90,91 The principle of Airyscan is that instead of simply rejecting 
any light not captured by the confocal pinhole, additional detector elements will 
collect this light and reconstruct the image with this light included to improve 
resolution. Combined with the LSM 880 with Fast Airyscan, we improved image 
quality and speed to get entire z-stacks in live cells before substantial ERES 
movement was observed. Zeiss introduced the Fast Airyscan module in May 2016, 
so Henderson et al. and Srinivasan et al. did not have access to this technology, 
seeing that their relevant papers came out in March 2016 and December 2010, 
respectively.83,89,91 The final point was also a product of improved instrumentation 
as using objective thresholding was possible with the more consistently high-
quality images produced by the LSM 880 with Fast Airyscan that was not possible 
on the old Nikon confocal microscope. 
1.5 Summary of Dissertation Work 
Improving public health is a major goal of many chemical biologists. This thesis 
demonstrates that the Lester lab is not an exception. I made contributions to three 
large contemporary public health issues throughout my graduate career: nicotine 
addiction, opioid use disorder, and COVID-19. In each, we utilized a unique set of 
skills and resources to understand new things about each of these issues. Like 
most things in science, we believe that this thesis builds on prior works and will 
serve as the foundation for further investigations. Comprehensive approaches to 
each of these problems are the best way to combat them, and we believe that this 
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Chapter 2: Synthesis and incorporation of a 
solvatochromic amino acid into the mouse muscle nAChR 
2.1 Abstract 
 Given the difficultly of acquiring ion channel structural information, we need 
creative solutions to understand the movements involved in activation. One of 
these solutions involves using solvatochromism. Solvatochromism refers to when 
fluorescent emission is modulated by the polarity of the fluorophore’s environment. 
Here, we decided to use non-canonical amino acid (NCAA) mutagenesis to 
incorporate an NCAA with these solvatochromic properties. We synthesized 4-N, 
N-dimethylamino-1,8-naphthalimide (4-DMN) and successfully incorporated it into 
the mouse muscle nAChR. The incorporation was achieved by injecting orthogonal 
tRNA that we aminoacylated in vitro with 4-DMN. Following verification of its 
incorporation with electrophysiology, we moved into imaging experiments. 
Specifically, we tried to observe 4-DMN fluorescence using total internal reflection 
fluorescence (TIRF) microscopy to visualize the plasma membrane selectively. 
Unfortunately, we could not observe 4-DMN fluorescence. The low incorporation 
efficiency inherent in the in vitro aminoacylation method prevented us from 
discriminating between 4-DMN in the receptors from unincorporated 4-DMN. In 
future studies, improved NCAA incorporation efficiency or a protocol that prevents 
visualization of unincorporated NCAAs will be required for success in this project.                                                                                              
2.2 Introduction 
 Structure determination is more complicated for membrane proteins than 
for soluble proteins because membrane proteins traverse a hydrophilic and 
hydrophobic environment.1 While detergents work well for soluble proteins, the 
hydrophilic/hydrophobic duality of membrane proteins makes detergents less 
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useful. It was only recently that any of the human heteromeric nAChR structures 
were experimentally solved by Ryan Hibbs and co-workers.2-4 Although these 
structures are valuable in nAChR research, structures are limited. They only 
capture one state of the receptor and are usually captured in unnatural 
environments. Since there is value in looking at protein movement in biologically 
relevant systems, researchers have been creative in their experimental design to 
fill this curiosity. 
 One exciting solution is to incorporate NCAAs into proteins at specific sites. 
This chapter will exclusively focus on the in vitro aminoacylation strategy that we 
explained in Chapter 1. This strategy will allow us to quickly incorporate residues 
with various functions without evolving different synthetases and optimizing them 
for selectivity versus canonical amino acids. One example is introducing 
fluorescent NCAAs.5-7 Fluorescent NCAAs are superior to fluorescent protein tags 
or cysteine-reactive dyes because NCAAs are significantly smaller than 
fluorescent proteins and more selective than cysteine-reactive dyes. Ultimately, 
NCAAs allow for the fluorescent detection of these proteins with minimal 
perturbation. 
 Going further with the fluorescent NCAAs, we focus specifically on using 
solvatochromic NCAAs. Solvatochromism refers to a special physical property 
where a fluorescent species undergoes a shift in their dipole moment upon 
excitation (Figure 2.1). These molecules differ from conventional fluorescent 
species in that their dipole moment significantly changes following excitation. The 
lifetime of the excited state is long enough that the molecules surrounding the 
fluorophore can readjust to decrease the entire system’s energy. Then the 
fluorophore emits a photon, returns to the ground state, and the surrounding 
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environment returns to its ground state arrangement around the fluorophore. The 
unique aspect of this particular fluorescent cycle is that there is a significant shift 
in the fluorophore’s dipole moment such that the surrounding environment will shift 
to accommodate it. The polarity of the surrounding environment will determine the 
wavelength of the photon emitted by the fluorophore. In general, the emitted 
wavelength will increase (the photon’s energy will decrease) as the environment’s 
polarity increases because it will lower the excited state’s new dipole better than a 
less polar environment.8-10 By measuring these emission shifts, one can determine 
if the solvatochromic molecule is in a polar or non-polar environment. 
 Bringing solvatochromism into biology can be tremendously useful. We 
know that all proteins have regions that are in polar or non-polar environments. 
Generally, the polar environments are “exposed” regions that interact with the 
aqueous solution in the cell. On the other hand, the non-polar environments are 
“buried” regions surrounded by other amino acids and have relatively lower polarity 
Figure 2.1 Scheme depicting solvatochromism. Excitation of the fluorophore causes a 
change in the molecule’s dipole moment (bottom-left to top-left). The surrounding 
environment will react to this change in dipole moment so that the excited fluorophore 
is in a more relaxed state (top-left to top-right). Fluorescent emission then occurs in this 
rearrangement environment (top-right to bottom-right). The emission wavelength is 
based on the environment since it directly influences the energy gap between the 
excited and ground state. Adopted from Loving, 2010. 
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than an aqueous solution. A 
particular residue is not 
necessarily always in an 
exposed or buried site since 
proteins can adopt an infinite 
number of conformations. 
Detecting if a specific residue 
is in a polar or non-polar 
environment in real-time is 
important to understanding a 
protein’s mechanism, but it is 
also a difficult experiment to 
design. Fortunately, 
solvatochromic NCAAs react 
to changes in polarity rapidly, 
and fluorescent excitation and 
emission happen within a 
millisecond, so real-time detection of an environment’s polarity is achievable. 
 To observe fluorescent NCAAs, we decided to use the in vitro 
aminoacylation technique in Xenopus oocytes. Unfortunately, this system is not 
well suited to most microscopy experiments because of the intense 
autofluorescence from the oocyte’s cytoplasm. Since we are interested in 
visualizing receptors on the surface, we decided to utilize total internal reflection 
fluorescence (TIRF) microscopy (Figure 2.2).11 Instead of directly irradiating the 
sample, the excitation light is directed at an angle to reflect all photons away from 
Figure 2.2 Principles of TIRF microscopy. (A) In 
epifluorescence microscopy, the excitation light 
hits the sample at a 90° angle, allowing for 
maximum sample penetration. (B) Conversely, 
TIRF microscopy uses total internal reflection so 
that excitation penetration is only ~100 nm. This 
typically only allows visualization of the plasma 
membrane and anything very close to it. We 
decide to use TIRF microscopy because it will 
remove much of the autofluorescence that comes 
from inside the Xenopus oocyte and makes them 
difficult to use in conventional microscopy. 
Adopted from Mattheyses 2010. 
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the sample. However, the evanescent wave produced can penetrate the sample 
and excite molecules. However, the evanescent wavefront will decay exponentially 
with distance such that only ~100 nm of the sample will be illuminated. This roughly 
corresponds to the width of the coverslip and the plasma membrane. Therefore, 
this illumination section is perfect for our experiments because this will not excite 
the oocyte cytoplasm.  
 Here, we incorporated a solvatochromic amino acid, 4-DMN, into the 
mouse muscle nicotinic acetylcholine receptor (mm nAChR) to visualize protein 
conformation changes. The mm nAChR is made up of 5 subunits. From the 
extracellular side, the subunits have a counterclockwise order of αγαδβ.12 The 
Imperiali group observed a shift in the emission spectrum when there is a shift in 
the polarity of 4-DMN’s environment.13 We were able to aminoacylate 4-DMN onto 
THG73, an orthogonal tRNA, in vitro for NCAA incorporation into Xenopus laevis 
oocytes. Using in vitro aminoacylation is substantially easier than developing a 
novel synthetase for 4-DMN.14 Using two-electrode voltage-clamp 
electrophysiology, we were able to verify that 4-DMN was incorporated into the 
mm nAChR. Unfortunately, the transition to microscopy was unsatisfactory due to 
low incorporation rates and high fluorescence from the plasma membrane due to 
unincorporated 4-DMN.  
2.3 Results and Discussion 
2.3.1 Synthesis of 4-DMN and ligation onto THG73 
 To incorporate 4-DMN into mm nAChR, we had to synthesize and append 
the amino acid onto an orthogonal tRNA. Fortunately, Loving and co-workers have 
already synthesized 4-DMN, and the remaining steps to ligate it onto THG73 have 
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been carried out numerous times with a wide range of amino acids.5,13,15-17 The 
synthetic scheme is shown in Figure 2.3.  
While the organic chemistry was straightforward, we wanted to confirm the 
photochemical properties of 4-DMN, particularly after a mock 4,5-dimethoxy-2-
nitrobenzyl (NVOC) deprotection. Since NVOC deprotects under ultraviolet (UV) 
light, we needed to confirm that the fluorescent properties of 4-DMN survived as 
some fluorophores will be damaged by UV light. We performed these experiments 
before conjugation to cytosine-adenine dinucleotide (dCA) since NVOC 
deprotection will cause hydrolysis of the dCA. We found that we still observe 
solvatochromism, and there is no significant drop in fluorescence after UV 
irradiation (Figure 2.4).  
We then completed the dCA and THG73 conjugation and confirmed that 4-
DMN was ligated onto the tRNA via mass spectrometry. 
 
2.3.2 Confirming 4-DMN incorporation in mm nAChR 
 Although the end goal for this project is to observe 4-DMN on the mm 
nAChR through a microscope, microscopy is not the most sensitive method to 
confirm that 4-DMN is being incorporated into the protein. Instead, we use TEVC 
Figure 2.3 Synthesis of 4-DMN and ligation onto the orthogonal tRNA, THG73. 
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electrophysiology. In our experience, differentiating between signal and noise is 
easier in electrophysiology than in microscopy. Using THG73 charged with 4-DMN, 
we could selectively incorporate 4-DMN at a specific residue.14  
 We tested several different sites to see if 4-DMN could be successfully 
incorporated into the mm nAChR. Some sites are very sensitive to changes and 























































Figure 2.4 The photochemical properties of 4-DMN. As the solvent 
(environment) becomes more polar, the emission wavelength increases. (A) 4-
DMN was excited by the absorbance maxima in each solvent, which also red-
shifted as solvent polarity increased (cyclohexane = 402 nm, dichloromethane 
= 430 nm, H2O = 444 nm. (B) Contrary to expectations of a decreased 
















certain sites will 
have greater than 
average read-
through events.16 
Since 4-DMN is 
larger than any of 
the canonical 
amino acids, we decided to begin with sites that have already been used to 
incorporate fluorophores either directly via NCAA mutagenesis or via tethering 
through a cysteine residue. These residues are A19’ (the prime notation is used to 
number residues going up a transmembrane helix where numbering starts on the 
intracellular side of the helix) on the β subunit and D70 on the α subunit.5,12 
Unfortunately, both of these sites produced larger currents with our negative 
controls, suggesting that read-through may have been too high.  
 Going away from the more promiscuous sites, we next tested the TrpB site 
(W149) on the α subunit and  L9’ (L278) on the α subunit.18-20 We decided to go 
with these sites because we know they have significant roles in channel activation, 
thus read-through at these residues will be more drastic than at the A19’ or D70 
site. Both of these residues had higher currents when we used a 4-DMN-charged 
tRNA over the 76mer control, with the L9’ site giving a significant difference 
(Figure 2.5). Although it was surprising that so many sites gave currents with the 
Figure 2.5 Integrity of the different residues for amber codon 
suppression. Xenopus oocytes were injected with 25 ng 
mRNA with the amber stop codon incorporated at the site 
listed at the bottom of each column along with 40 ng of tRNA. 
The only significant difference between the 76mer and the 4-
DMN samples were when the αL278 site was suppressed.  






















76mer control, it is reassuring that we could incorporate 4-DMN at the L9’ site. 
Further, in terms of the goals of this project, we should see changes in the polarity 
surrounding this site. The L9’ residue is expected to occlude the pore in the inactive 
states (hydrophilic environment) and rotate to face the other transmembrane 
helices upon activation (hydrophobic environment).20  
 
2.3.3 Efforts to observe 4-DMN incorporated into mm nAChRs in Xenopus oocytes 
 Since we successfully incorporated 4-DMN into mm nAChR, we decided to 
move into microscopy experiments to see if we could visualize these receptors 
using 4-DMN fluorescence. At this point, we exclusively utilized TIRF microscopy 
because the autofluorescence from the Xenopus oocyte yolk will overwhelm any 
signal from 4-DMN.  
 First, we wanted to see what oocytes looked like when we just injected 4-
DMN-charged tRNA. This is an important negative control since we expect 
incorporation efficiency to be less than 100%, thus we want to know what an oocyte 
would look like if 4-DMN is not incorporated into the mm nAChR. Unfortunately, 
Figure 2.6 Preliminary TIRF experiments to see if unincorporated 4-
DMN gave substantial signal at the plasma membrane. (A) An 
uninjected oocyte. (B) An oocyte injected with 4-DMN-charged tRNA 
and no mRNA. The intense signal from panel (B) suggests that we 




there is intense fluorescence from the plasma membrane after 4-DMN-charged 
tRNA injection (Figure 2.6). This finding is consistent with the structure of 4-DMN 
as it is a hydrophobic molecule that will localize to hydrophobic regions. Indeed, 
when we performed experiments looking at where 4-DMN localizes in HEK293T 
cells, we found that it did localize in the plasma membrane (Figure 2.7). 
Unfortunately, despite our attempts to use other solvatochromic amino acids, we 
could not overcome this barrier. 
 
Figure 2.7 4-DMN localizes to the plasma membrane. (A) Confocal images of 
HEK293T cells. (A1) 4-DMN channel (A2) Plasma membrane marker. (A3) Merged. 
(B) Co-linearization line analysis showing that the peaks coincide, suggesting that 

































































































































 Despite our best attempts at this ambitious project, we ultimately came 
short of our goal of visualizing mm nAChRs using a solvatochromic amino acid. 
Unlike previous attempts performed by Rigo Pantoja and co-workers, we could not 
definitively observe receptors with a fluorescent amino acid.5 While we were both 
able to incorporate the NCAA, in Pantoja et al., they observed ~10-fold more 
fluorescent puncta in their experimental samples than in their negative controls 
(without mRNA). Unfortunately, we were not able to replicate these results with 4-
DMN.  
 Nonetheless, the project was not entirely for naught. We were able to 
synthesize and incorporate 4-DMN into the mm nAChR. Additionally, the insights 
with 4-DMN cellular localization will guide further efforts with this project. More 
hydrophilic fluorophores should be preferred to avoid plasma membrane 
localization of unincorporated NCAA. Furthermore, more in vitro methods could be 
explored. Miles et al. isolated the plasma membrane to restrict their observations 
to the plasma membrane.21 While TIRF microscopy is good at limiting excitation to 
near the coverslip, it is not perfect. By isolating membranes, it leaves no doubt that 
we would exclusively observe signals from the plasma membrane. Additionally, 
using plasma membrane isolates, we could wash the plasma membrane and 
potentially remove unincorporated 4-DMN. Alternatively, one could explore 
developing an orthogonal synthetase/tRNA for 4-DMN to move into mammalian 
cell cultures.22 These systems lend themselves more easily to microscopy and will 
not be restricted to membrane-bound targets. However, evolving a 
synthetase/tRNA is a monumental task. Lastly, other photochemical properties 
could be examined. Fluorescent lifetime measurements have become routine 
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recently, and depending on how the lifetime changes between 4-DMN in the lipid 
bilayer versus the mm nAChR, one could isolate the mm nAChR signal.23-25  
 
2.5 Materials and Methods 
2.5.1 Synthesis 
All reagents and solvents were procured from Sigma-Aldrich unless 
otherwise stated, and used as received. All organic reactions were carried out 
under an argon atmosphere in a flame-dried flask with a sealed rubber septum. 
 
4-N,N-dimethylamino naphthalic anhydride (4DMNA) Synthesis was largely 
based on the protocol used by Kollar et al.26 A solution of 4-bromo-1,8-napthalic 
anhydride (1.12 g, 4.0 mmol) in 3-methyl-1-butanol (28 mL) was heated to 132°C 
and stirred.26 To this solution, 3-dimethlyaminopropionitrile (1.6 g, 16 mmol) was 
added and allowed to stir at 132°C for 12 hours. Crystals formed and were filtered 
and washed with water and cold hexanes to yield 0.7 g of orange product (73%) 
1H-NMR (300 MHz, CDCl3): δ 3.18 (s, 6H), 7.11 (d, 8.4 Hz, 1H), 7.67 (t, 7.3 Hz, 




NH2-4DMN-COOH Synthesis was largely based on the protocol used by Loving et 
al.13 Briefly, (S)-3-amino-2- (Boc-amino)-propionic acid (200 mg, 0.98 mmol) and 
NaHCO3 (400 mg, 4.9 mmol) were dissolved in 5 mL dH2O. A separate flask was 
used to dissolve 4DMNA (0.26 g, 1.1 mmol) in dioxane (25 mL) which was 
evacuated of air, charged with N2, stirred, and brought to reflux. Once at reflux, the 
amino acid solution was slowly added to the 4DMNA solution. The reaction was 
allowed to proceed at reflux for 30 minutes before allowing to cool to room 
temperature. The solution was then concentrated via a rotary evaporator, diluted 
with dH2O (20 mL), and washed with diethyl ether (3x20 mL). The aqueous layer 
was acidified and extracted with dichloromethane (3x30 mL). Organic layers were 
combined, dried over MgSO4, filtered, and concentrated. The solid was then 
dissolved in 50% trifluoroacetic acid in dichloromethane and stirred for 90 minutes 
at room temperature. The solution was then concentrated by azeotroping with 
toluene to yield 230 mg (70%) of an orange solid. 1H NMR (300 MHz, Methanol-
d4) δ 8.58 (m, 2H), 8.47 (d, 8.0 Hz, 1H), 7.75 (t, 8.0 Hz, 1H), 7.24 (d, 8.4 Hz, 1H), 





Nvoc-4DMN-dCA To NH2-4DMN-COOH (164 mg, 0.5 mmol) was added 4,5-
dimethoxy-2-nitrobenzyl chloroformate (Nvoc-Cl) (162 mg, 0.59 mmol), Na2CO3 
(62 mg, 0.59 mmol), dioxane (50 mL) and water (34 mL), and stirred overnight at 
room temperature. The resulting solution was then concentrated and not purified 
further. Dimethylformamide (3.25 mL), 2-chloroacetonitrile (3.25 mL), and 
trimethylamine (0.23 mL) were added and stirred for 36 hours at room temperature. 
The resulting solution was concentrated, dissolved in acetonitrile, and purified via 
reverse-phase HPLC. Positive fractions were identified by ESI-MS and lyophilized. 
The solid Nvoc-4DMN-cyanomethyl ester was then dissolved in 
dimethylformamide (1 mL), added to a vial containing 5 mg tertbutyl-ammonium 
and 5 mg dCA, and stirred for 36 hours. The resulting solution was diluted to 10ml 
1:1 acetonitrile/water and purified via reverse-phase HPLC. ESI-MS: 1185 [M+H].  
 
2.5.2 Mouse Muscle nAChR Molecular Biology  
Nvoc-4DMN-dCA was ligated onto a THG73 74mer using T4 RNA ligase 
to generate Nvoc-4DMN-THG73 (MALDI-MS, m/z= 24857.7, calc: 24845). Before 
injection, Nvoc-4DMN-THG73 was decaged using a 365 nm LED rated for 1 W for 
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150 s. The formation of NH2-4DMN-THG73 was verified by MALDI and 
immediately injected into oocytes along with the appropriated mRNA. Mutated 
mRNA strands were generated from pAMV plasmid expressing the mouse muscle 
nAChR subunits and subjecting them to QuikChange PCR (Stratagene) to insert 
the mutations into the plasmid. The PCR product is then electroporated into E. coli 
and grown on a LB Agar plate at 37°C for 18 hours. Colonies were then picked 
and grown up in 2XYT media at 37°C for 12 hours. Bacteria was then subjected to 
a MiniPrep (Qiagen) and sequenced to confirm the mutation. Positive results were 
then linearized using the NotI restriction enzyme and translated to mRNA using a 
T7 mMessage mMachine kit (Thermo Fisher).  
 
2.5.3 Microinjection 
Stage V-VI Xenopus laevis oocytes were injected with mRNA and tRNA as 
described previously.27,28 Each oocyte was injected with approximately 50 nL of 
solution with 10-25 ng mRNA and approximately 40 ng tRNA. Oocytes were 
injected twice over a 48 hours incubation time and either recorded in a two-
electrorode voltage clamp on a OpusXpress 6000A or devitallinized and imaged 
using TIRF microscopy on a Zeiss Elyra microscope at the Translational Imaging 
Center at the University of Southern California. 
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Chapter 3: Identification and biophysical analysis of the 
menthol binding site in the α4β2 nicotinic acetylcholine 
receptor 
*This chapter is partly adapted from: Brandon J. Henderson, Stephen 
Grant, et al. Menthol stereoisomers exhibit different effects on α4β2 nACh 
upregulation and dopamine neuron spontaneous firing. eNeuro, 2018. 
3.1 Abstract 
 Smoking is the leading cause of preventable death, with tobacco being 
responsible for over 7 million deaths each year. The addictive compound in 
tobacco, nicotine, will bind to several receptors in the brain to elicit pleasurable 
sensations that lead to addiction. However, inhaling burning gas during smoking 
can be uncomfortable. To overcome these unpleasant burning sensations, 
tobacco companies make cigarettes with menthol, a cooling agent, to make their 
products more attractive. For decades, menthol was thought to be a flavorant 
without any significant effects on the brain. Unfortunately, recent work has 
demonstrated that not only does menthol have a neurobiological effect, but it may 
accentuate nicotine addiction. One explanation for this observation is that menthol 
upregulates α4-containing (α4*) nAChRs, the proteins most responsible for the 
effects of nicotine. Additionally, menthol is a negative allosteric modulator of the 
α4β2 nAChRs. However, the binding site for menthol on α4β2 had not been 
determined. Here, using molecular dynamics (MD) and TEVC electrophysiology, 
we determine that menthol is binding to α4β2 at the pore and mutating the L9’ site 
alters menthol’s potency as a negative allosteric modulator. These results confirm 
that menthol can bind to α4β2. Furthermore, we determine that the effect is 
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primarily based on the size at the 9’ residue and one menthol molecule is sufficient 
for receptor inhibition. Together, the menthol binding site’s experimental 
determination on α4β2 gives further proof that menthol is not an innocent 
bystander in nicotine addiction. 
3.2 Introduction 
 Humans have consumed tobacco for millennia, but it was only in the past 
few decades that we have come to terms with its adverse health effects. In 1964, 
the United States Surgeon General issued a warning about smoking’s health 
hazards.1 Since then, scientists and politicians have worked together to protect 
people from tobacco’s harmful effects. Nevertheless, millions of people and 
hundreds of billions of dollars are lost globally due to tobacco. A primary challenge 
in addressing nicotine addiction, from a scientific standpoint, is that it is a neuronal 
condition. The brain remains one of the most mysterious things that we know. 
Nonetheless, we are making progress in understanding the brain, and we certainly 
know more about nicotine addiction than we did even a year ago.  
 One of the most important discoveries was finding the neuronal nAChRs. 
These are pentameric ligand-gated ion channels that are composed of α and β 
subunits.2 Given that there are six unique α subunits and three unique β subunits 
found in the brain, there is incredible diversity in the types of nAChRs that can 
assemble in the brain. Of the hundreds of possible nAChR combinations, perhaps 
the most important one to nicotine addiction is the nAChR composed of α4 and β2 
subunits, the α4β2 nAChR.3,4 Activation of α4* nAChRs is sufficient for reward and 
tolerance and nicotine self-administration is attenuated in β2-knock out mice.5,6 
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Combined with the prominence of α4β2 nAChRs in the brain, we decided to focus 
specifically on the α4β2 nAChR. 
 While unflavored cigarettes are in high demand, a large portion of nicotine 
consumers prefer a flavored product. For most of its history, tobacco flavors were 
not regulated, but this ended in 2009 when the Family Smoking Prevention and 
Tobacco Control Act limited flavors to just menthol. Menthol provides a cooling 
sensation from the activation of the transient receptor potential cation 
channel subfamily melastatin member 8 (TRPM8).7 Menthol cigarettes control a 
large portion of the market (currently, approximately 25% of all smokers use 
menthol cigarettes) and was thought to have no meaningful impact on addiction.8 
Unfortunately, the latter statement proved to be incorrect. Firstly, menthol cigarette 
smokers have a harder time quitting and have a greater dependence on their 
cigarettes than non-mentholated cigarette smokers.9,10 There are three potential 
reasons for these observations (and indeed they may all play a role): menthol 
makes the cigarettes taste better than non-mentholated cigarettes, menthol 
Figure 3.1 Menthol alone does not change place preference (a), but will increase 
nicotine-related reward (b). (Henderson 2017) 
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decreases nicotine metabolism, and menthol has a neurobiological effect on 
menthol cigarette smokers.11 Recent work gives credence to the third reason as 
injected menthol will enhance the nicotine-related reward (Figure 3.1).12 Further 
studies revealed that dopaminergic neurons treated with menthol and nicotine 
would have more α4* and α6* receptors on the plasma membrane, and these 
receptors will be biased towards the higher sensitivity confirmation.12 We also see 
α4* receptors upregulated when the dopaminergic neurons are treated with only 
menthol, although menthol alone will bias towards the less sensitive confirmation.13  
 In addition to menthol’s cellular effects, menthol has been found to affect 
several neuronal receptors directly, including α4β2.14 Menthol is a negative 
allosteric modulator for many of these receptors.15-20 Specifically, menthol will 
inhibit currents through these receptors without affecting agonist EC50, 
demonstrating that menthol will not compete for the agonist binding site. Although 
these results are not tremendously physiologically relevant because the IC50 for 
menthol is several orders of magnitude higher than the concentrations found in a 
menthol smoker’s brain, they show a direct interaction between menthol and these 
important neuroreceptors. Nonetheless, other methods for channels modulation 
do not involve direct binding to the receptor. For example, the lipid environment 
can play a major role in membrane protein function, so a   small molecule can 
induce changes to a membrane protein by altering the surrounding lipids.21-23 Since 
menthol will partition primarily out of solution and into the lipid bilayer, altering the 
membrane environment is a possible mechanism for altering channel activity. 
 Here, we tested our hypothesis that menthol was binding to α4β2 by 
looking for the menthol binding site for α4β2. We turned to our collaborators in the 
Clemons (Caltech) and Tajkhorshid (UIUC) labs for MD simulations to give us 
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insight into where menthol may interact with α4β2. Using the crystal structure 
solved by the Hibbs group in 2016, we could predict the residues that menthol 
would likely explore.24 Although the MD simulations predict the most of the menthol 
will enter the lipid bilayer, one of the trajectories predicts that menthol will enter the 
channel and populate an area around the 9’ (the prime numbering system starts 
numbering residues from the cytoplasmic side of the helix) site on the M2 helix.25 
Going forward with this prediction, we experimentally tested the 9’ site by mutating 
it to different residues to see if it affected menthol’s IC50. Indeed, menthol’s IC50 
depended on the residue’s size at the 9’ site, where larger residues gave a lower 
IC50. We also found that one menthol molecule was sufficient for channel inhibition, 
consistent with our MD simulations. The identification of the menthol binding site, 
thus proving that menthol directly interacts with neuronal proteins, supports why 
menthol is a dangerous molecule to include in nicotine products.  
3.3 Results and Discussion 
3.3.1 Changing the residue at the 9’ site in the M2 helix alters menthol’s IC50 
 At a set concentration of agonist, the presence of menthol will cause fewer 
ions to pass through the α4β2 nAChR than when menthol is absent. This inhibition 
is directly related to the concentration of menthol in the solution, where a higher 
concentration of menthol will inhibit the channel more. Plotting the concentration 
of menthol against the number of ions passing through the channel (the current) 







𝑛                                    (1) 
where n is the Hill coefficient, we can measure the menthol’s ability to inhibit the 
α4β2 nAChR using TEVC electrophysiology.26 When we have a candidate site for 
the menthol binding site, we would mutate it and then remeasure the IC50 for 
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menthol to see if the mutation changed menthol’s ability to negatively modulate the 
α4β2 nAChR.  
 After several unsuccessful attempts to alter menthol’s IC50, we finally 
generated a significant shift by mutating the 9’ site on the M2 helix (Figure 3.2). 
We find that this site is the same for both enantiomers of menthol, with (-)-menthol 
being more potent than (+)-menthol. This finding is consistent with a calculation 
performed by Rezvan Shahoei of the Tajkhorshid group (Figure 3.3).  These 
results suggest that menthol can enter the pore and essentially block the channel, 
thus preventing ions from flowing through it. Channel block is a common strategy 
to antagonize ion channels, although many of them are large cations that utilize 
the cell membrane’s negative potential, ensuring that the large cation stays in the 
Figure 3.2 Changing the residue at the 9’ site on the M2 helix changes the IC50 
curve for (A)(-)-menthol and (B) (+)-menthol for the (α4)2(β2)3 receptor. (C) 
Inhibition with 100 µM (-)-menthol is higher than inhibition with 100 µM (+)-menthol. 
P-values are calculated from a Student’s t-test. ****, p < 0.001; ***, p<0.005, **, 
p<0.01. 
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pore and prevents smaller ions from passing through the membrane.27-29 Here, 
menthol seems to be engaging with the pore because it is more stable near the 
pore’s hydrophobic residues than in the bulk water. 
 
3.3.2 Menthol inhibition is directly related to the length of the 9’ residue 
 Since each mutant gave a unique menthol IC50 value, we had a decent data 
set to do structure-function analysis. The amino acids vary in their polarity, size, 
and functional groups, which allows us to probe for various trends. In addition to 
the reduced AA index 
produced by Kibinge and 
co-workers, we also  
probed for end-to-end 
residue length, 
determined with a 
Hartree-Fock 
calculation.30 Here, we 
find the best correlation 
with the end-to-end 
residue length (Figure 
3.4). This observation is 
consistent with our 
hypothesis that menthol 
is simply blocking the 
pore. We believe that we 
do not see a dependence 
Figure 3.3 MD simulation where menthol (space-filling 
model) binds to the channel pore in the α4β2 nAChR 
(ribbons). The sticks surrounding the α4β2 nAChR 




















on polarity because all residues provide a more nonpolar environment than water. 
Instead, the residue must be large enough (so that the pore is small enough) for 
menthol to plug the pore. 
 Arguably the most important 
intermolecular interaction in proteins is the 
hydrogen bond, and we wanted to ensure 
that menthol will not bond to the 9’ residue 
through a hydrogen bond. Since there are 
no canonical amino acids that differ in just 
the presence or absence of a hydrogen 
bond, we turned to NCAAs. Here, we will 
pick residues that will be very close to the 
same size but differ in the replacement of 
methylene for oxygen, thereby allowing 
this residue to become a  hydrogen bond 
acceptor with a  minimal change in sterics. 
Specifically, we compared the IC50 values between a receptor with isoleucine at 
the 9’ position with a receptor with O-methyl threonine at the 9’ position (Figure 
3.5). Since there is no difference between the IC50’s in these two receptors, we are 
confident that hydrogen bonding is not important for menthol to inhibit the α4β2 
nAChR. 
 
3.3.3 Only one menthol molecule is required for receptor inhibition 
 In addition to measuring potency, the Hill equation can predict relative 
cooperativity between ligand binding events through the Hill coefficient.26 For 
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menthol and α4β2, we can use the Hill coefficient to estimate the number of 
menthol molecules required for receptor inhibition. We averaged the Hill coefficient 
between all of the mutants we made and found that for both enantiomers of 
menthol, the mean Hill coefficient is one, suggesting that one menthol molecule is 
sufficient for α4β2 inhibition (Figure 3.6). 
 
3.3.4 (-)-menthol is more potent than (+)-menthol 
There are eight stereoisomers of menthol, but tobacco products almost 
exclusively contain (-)-menthol.31 Additionally, (-)-menthol is the most common 
stereoisomer found in plants and has the lowest EC50 for TRPM8.32 Previous work 
in our lab demonstrated that (-)-menthol will upregulate plasma membrane levels 
of α4β2, reduce the firing frequency of dopamine neurons, and decrease dopamine 
neuron excitability, while (+)-menthol does not.25 Since the binding mechanism 
appears to be entirely based on sterics, we decided to compare the inhibitory 
potencies of (-)-menthol and (+)-menthol. We find that there is not a substantial 
difference between (-)-menthol and (+)-menthol in terms of inhibiting α4β2 (Figure 
3.7). This contrasts with what others have observed for the GABAA receptor, where 
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Figure 3.5 The presence of a hydrogen bond acceptor 




(+)-menthol was more potent than  (-)-menthol.15 These results suggest that the 
origin of menthol’s effects on plasma membrane α4β2 levels and dopaminergic 
neurons is not based on its ability to inhibit α4β2  since (+)-menthol inhibits α4β2, 
but it does not affect dopaminergic neurons or α4β2 plasma membrane levels. 
3.4 Conclusions 
  The increased consumption of nicotine in the past few years is troubling. 
Major components of the tobacco market are products that are flavored with 
menthol. For decades, this ingredient was thought to be inactive in the brain, but 
recent work shows that menthol will alter the dopaminergic neurons and increase 
nicotine-related reward. Our work in this chapter expands our understanding of 
menthol. The α4β2 nAChRs are major players in nicotine addiction, and knowing 
how menthol binds to these receptors gives further evidence that menthol is not 
an innocuous flavorant. Menthol directly interacts with the α4β2 nAChRs by 
binding to the pore and essentially preventing ions from flowing through the 
channel. There are still many questions surrounding the mechanism of menthol’s 
Figure 3.6 The average Hill coefficient for the menthol 
concentration-response curves is ~1, suggesting that one 







R e c e p to rs  w ith












( - ) -M e n th o l
(+ )-M e n th o l




neurobiological effects, and learning more about menthol is paramount to 
addressing nicotine addiction. 
 
3.5 Materials and Methods 
3.5.1 Reagents  
(-)-Menthol (product number 63658), (+)-menthol (product number M2780), 
and acetylcholine (ACh) chloride (product number A6625) were obtained from 
Sigma-Aldrich. 
 
3.5.2 Oocyte preparation and injection  
Rat α4 and β2 nAChR subunits were in pGEMhe vectors. The mRNAs were 
prepared from linearized DNA, using a T7 mMessage mMachine kit (Ambion), and 
were purified with the RNeasy Mini Kit (Qiagen). Xenopus laevis stage V and VI 
oocytes were harvested via standard protocols.33 The α4 and β2 mRNAs were 
mixed in a 10:1 ratio to obtain the (α4)3(β2)2 receptor or 1:10 ratio to obtain the 
(α4)2(β2)3 receptor. For unnatural amino acid incorporation, a TAG codon was 
incorporated into the site of interest, and 40 ng of unnatural amino acid-coupled 
THG73 tRNA was added to the injection solution. The α4 and β2 mRNAs were 





mixed in a 100:1 ratio by mass to obtain the (α4)3(β2)2 receptor for these unnatural 
amino acid experiments. A total of 50 nL of the RNA mixture were injected into 
each oocyte, delivering an mRNA mass total of 22 ng for wild-type or conventional 
mutant experiments. After injection, the oocytes were incubated at 18°C in ND96 
medium (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5mM HEPES at pH 7.5) 
enriched with theophylline, sodium pyruvate, and gentamicin for 48 h before 
recording. 
 
3.5.3 Oocyte electrophysiology  
The OpusXpress 6000A (Molecular Devices) in two-electrode voltage-
clamp mode was used for all electrophysiological recordings. ACh was dissolved 
to 1 M stock solutions in ND96 Ca2+ free buffer. The holding potential was set to  -
60 mV, and the running buffer used was ND96 Ca2+ free buffer for all experiments. 
Drug applications used 1 mL of drug solution applied over 15 s followed by a 5 min 
buffer wash at a rate of 3 mL/min. Data were sampled at 50 Hz and low-pass 
filtered at 5 Hz. Averaged and normalized data were fit to the Hill equation to 
generate Hill coefficient (nH) and EC50 or IC50 values. All currents for the activity 
testing were normalized to the maximum current (Imax) produced by the oocyte. 
Error bars represent S.E.M. values. 
3.6 References 
1 Jamal, A. et al. Current cigarette smoking among adults - United States, 
2005-2014. MMWR-Morb. Mortal. Wkly. Rep. 64, 1233-1240 (2015). 
2 Pons, S. et al. Crucial Role of α4 and α6 Nicotinic Acetylcholine Receptor 
Subunits from Ventral Tegmental Area in Systemic Nicotine Self-
Administration. J. Neurosci. 28, 12318-12327, doi:10.1523/jneurosci.3918-
08.2008 (2008). 
3 Xiao, C. et al. Chronic nicotine selectively enhances α4β2*nicotinic 
acetylcholine receptors in the nigrostriatal dopamine pathway. J. Neurosci. 
29, 12428-12439, doi:10.1523/jneurosci.2939-09.2009 (2009). 
58 
 
4 Xiu, X., Puskar, N. L., Shanata, J. A., Lester, H. A. & Dougherty, D. A. 
Nicotine binding to brain receptors requires a strong cation-π interaction. 
Nature 458, 534-537, doi:10.1038/nature07768 (2009). 
5 Picciotto, M. R. et al. Acetylcholine receptors containing the β2 subunit are 
involved in the reinforcing properties of nicotine. Nature 391, 173-177 
(1998). 
6 Tapper, A. R. et al. Nicotine activation of alpha 4*receptors: Sufficient for 
reward, tolerance, and sensitization. Science 306, 1029-1032, 
doi:10.1126/science.1099420 (2004). 
7 Andersson, D. A., Chase, H. W. N. & Bevan, S. TRPM8 activation by 
menthol, icilin, and cold is differentially modulated by intracellular pH. J. 
Neurosci. 24, 5364-5369, doi:10.1523/jneurosci.0890-04.2004 (2004). 
8 Thompson, M. F. et al. Menthol enhances nicotine-induced locomotor 
sensitization and in vivo functional connectivity in adolescence. J. 
Psychopharmacol. 32, 332-343, doi:10.1177/0269881117719265 (2018). 
9 Ahijevych, K. & Garrett, B. E. The role of menthol in cigarettes as a 
reinforcer of smoking behavior. Nicotine Tob. Res. 12, S110-S116, 
doi:10.1093/ntr/ntq203 (2010). 
10 Gandhi, K. K., Foulds, J., Steinberg, M. B., Lu, S. E. & Williams, J. M. Lower 
quit rates among African American and Latino menthol cigarette smokers 
at a tobacco treatment clinic. Int. J. Clin. Pract. 63, 360-367, 
doi:10.1111/j.1742-1241.2008.01969.x (2009). 
11 Benowitz, N. L., Herrera, B. & Jacob, P., 3rd. Mentholated cigarette 
smoking inhibits nicotine metabolism. J. Pharmacology and Experimental 
Therapeutics 310, 1208-1215, doi:10.1124/jpet.104.066902 (2004). 
12 Henderson, B. J. et al. Menthol enhances nicotine reward-related behavior 
by potentiating nicotine-induced changes in nAChR function, nAChR 
upregulation, and da neuron excitability. Neuropsychopharmacology 42, 
2285-2291, doi:10.1038/npp.2017.72 (2017). 
13 Henderson, B. J. et al. Menthol alone upregulates midbrain nAChR, alters 
nAChR subtype stoichiometry, alters dopamine neuron firing frequency, 
and prevents nicotine reward. J Neurosci 36, 2957-2974, 
doi:10.1523/jneurosci.4194-15.2016 (2016). 
14 Pandya, A. & Yakel, J. L. Allosteric modulators of the α4β2 subtype of 
neuronal nicotinic acetylcholine receptors. Biochem. Pharmacol. 82, 952-
958, doi:10.1016/j.bcp.2011.04.020 (2011). 
15 Hall, A. C. et al. Modulation of human GABAA and glycine receptor currents 
by menthol and related monoterpenoids. Eur. J. Pharmacol. 506, 9-16, 
doi:10.1016/j.ejphar.2004.10.026 (2004). 
16 Hans, M., Wilhelm, M. & Swandulla, D. Menthol suppresses nicotinic 
acetylcholine receptor functioning in sensory neurons via allosteric 
modulation. Chem. Senses 37, 463-469, doi:10.1093/chemse/bjr128 
(2012). 
17 Ashoor, A. et al. Menthol binding and inhibition of α7-nicotinic acetylcholine 
receptors. PLoS One 8, e67674, doi:10.1371/journal.pone.0067674 
(2013). 
18 Ashoor, A. et al. Menthol Inhibits 5-HT3 Receptor-Mediated Currents. J. 
Pharmacol. Exp. Ther. 347, 398-409, doi:10.1124/jpet.113.203976 (2013). 
59 
 
19 Ton, H. T. et al. Menthol enhances the desensitization of human α3β4 
nicotinic acetylcholine receptors. Mol Pharmacol 88, 256-264, 
doi:10.1124/mol.115.098285 (2015). 
20 Oz, M., Lozon, Y., Sultan, A., Yang, K. H. S. & Galadari, S. Effects of 
monoterpenes on ion channels of excitable cells. Pharmacol. Ther. 152, 
83-97, doi:10.1016/j.pharmthera.2015.05.006 (2015). 
21 Brannigan, G., LeBard, D. N., Henin, J., Eckenhoff, R. G. & Klein, M. L. 
Multiple binding sites for the general anesthetic isoflurane identified in the 
nicotinic acetylcholine receptor transmembrane domain. PNAS 107, 
14122-14127, doi:10.1073/pnas.1008534107 (2010). 
22 Henault, C. M. et al. The role of the M4 lipid-sensor in the folding, trafficking, 
and allosteric modulation of nicotinic acetylcholine receptors. 
Neuropharmacology 96, 157-168, doi:10.1016/j.neuropharm.2014.11.011 
(2015). 
23 Yin, Y. & Lee, S. Y. Current view of ligand and lipid recognition by the 
menthol receptor TRPM8. Trends Biochem.Sci. 45, 806-819, 
doi:10.1016/j.tibs.2020.05.008 (2020). 
24 Morales-Perez, C. L., Noviello, C. M. & Hibbs, R. E. X-ray structure of the 
human α4β2 nicotinic receptor. Nature 538, 411-415, 
doi:10.1038/nature19785 (2016). 
25 Henderson, B. J. et al. Menthol stereoisomers exhibit different effects on 
α4β2 nAChR upregulation and dopamine neuron spontaneous firing. 
eNeuro 5, eneuro.0465-0418.2018, doi:10.1523/eneuro.0465-18.2018 
(2018). 
26 Prinz, H. Hill coefficients, dose–response curves and allosteric 
mechanisms. Journal of Chemical Biology 3, 37-44, doi:10.1007/s12154-
009-0029-3 (2010). 
27 Pascual, J. M. & Karlin, A. Delimiting the binding site for quaternary 
ammonium lidocaine derivatives in the acetylcholine receptor channel. J. 
Gen. Physiol. 112, 611-621, doi:10.1085/jgp.112.5.611 (1998). 
28 Charnet, P. et al. An open-channel blocker interacts with adjacent turns of 
α-helices in the nicotinic acetylcholine receptor. Neuron 4, 87-95, 
doi:10.1016/0896-6273(90)90445-l (1990). 
29 Wang, C., Takeuchi, K., Pinto, L. H. & Lamb, R. A. Ion-channel activity of 
influenza-A virus M(2) protein - characterization of the amantadine block. 
Journal of Virology 67, 5585-5594, doi:10.1128/jvi.67.9.5585-5594.1993 
(1993). 
30 Kibinge, N., Ikeda, S., Ono, N., Altaf-Ul-Amin, M. & Kanaya, S. Integration 
of residue attributes for sequence diversity characterization of terpenoid 
enzymes. BioMed Research International 2014, 10, 
doi:10.1155/2014/753428 (2014). 
31 Chen, C., Luo, W. T., Isabelle, L. M., Gareau, K. D. & Pankow, J. F. The 
stereoisomers of menthol in selected tobacco products. A brief report. 
Nicotine Tob. Res. 13, 741-745, doi:10.1093/ntr/ntr031 (2011). 
32 Sherkheli, M. A. et al. Characterization of selective TRPM8 ligands and 
their structure activity response (SAR) relationship. J. Pharm. Pharm. Sci. 
13, 242-253, doi:10.18433/j3n88n (2010). 
33 Marotta, C. B., Dilworth, C. N., Lester, H. A. & Dougherty, D. A. Probing the 
non-canonical interface for agonist interaction with an α5 containing 
60 
 
nicotinic acetylcholine receptor. Neuropharmacology 77, 342-349, 





Chapter 4: Opioid receptor antagonists pharmacologically 
chaperone a mutant µ-opioid receptor via an endoplasmic 
reticulum exit site-dependent pathway 
This work was done in collaboration with Anand K. Muthusamy 
and Dr. Matthew J. Mulcahy 
4.1 Abstract 
Some opioid-related drug overdoses occur during relapse after naltrexone 
(Ntx) or naloxone treatment. These opioid receptor antagonists induce 
supersensitivity to µ-opioid receptor (MOR) agonists in vivo, thereby increasing the 
risk of overdose. The effects of opioid ligands on trafficking from the endoplasmic 
reticulum (ER) have been insufficiently studied. Endoplasmic reticulum exit sites 
(ERES) are a component in the trafficking of membrane proteins. Using 
fluorescently tagged Sec24 to visualize ERES and a highly ER-retained MOR point 
mutant, MOR[N190K], we measured ERES levels after incubation in various opioid 
receptor ligands. Data from sensitized emission Förster resonance energy transfer 
(FRET) show that MOR[N190K] interacts with Sec24D. By expressing 
MOR[N190K] and Sec24D-eGFP to visualize ERES in SH-SY5Y cells 
fluorescently, we observe that antagonists increase the fraction of the cytoplasm 
occupied by ERES. In contrast to the antagonists, the agonists, morphine, fentanyl, 
buprenorphine, and methadone, have no significant effect on ERES levels. 
Mutating S375, an important phosphorylation site for MOR internalization, did not 
cause morphine or fentanyl to become pharmacological chaperones. Two MOR 
allosteric modulators had no significant effect on ERES levels. Ntx did not change 





find that pharmacological chaperoning depends on functional coat protein I (COPI) 
vesicles. N-methylnaltrexone (Me-Ntx), a permanently charged analog, did not act 
as a pharmacological chaperone, suggesting that Me-Ntx would be safe if used 
more widely for its approved indications. Thus, understanding of chaperoning 
could lead to improved use of opioids. 
4.2 Introduction 
The MOR is the primary target for most clinically used analgesic opioids.1 
Understanding how the MOR enters and exits the plasma membrane is critical to 
understanding the causes of opioid use disorder.1-6 Chronic application of certain 
agonists results in decreased MORs on the plasma membrane. In the prevailing 
view (not challenged in this study), these agonists cause phosphorylation at the C-
terminus via G-protein receptor kinases, which induce β-arrestin binding and 
endocytosis.7 The opioid peptides and some synthetic alkaloid agonists, like 
fentanyl, broadly cause rapid endocytosis.8 In turn, researchers have tried to 
develop biased agonists that maintain analgesic properties while reducing 
dependence and tolerance.9  
In contrast, chronic doses of the two most common opioid antagonists, 
naltrexone (Ntx) and naloxone,10 decrease the number of MORs on the cell 
surface. This upregulation of surface levels of opioid receptors in response to 
antagonists causes supersensitivity in vivo.11 Supersensitivity is a health concern 
because these antagonists are prescribed for individuals recovering from opioid 
use disorder. This treatment is intended to prevent relapse from causing euphoria. 
However, if antagonists are not present and the patient relapses to opioid use, the 
supersensitivity causes a more potent effect than expected, increasing the risk of 





administration of the antagonist.12 If researchers find a way to prevent opioid 
receptor surface level upregulation, the health risks involved in prescribing opioid 
antagonists will decrease dramatically.  
Several mechanisms could underlie upregulation. Since certain agonists 
induce endocytosis, perhaps the prevention of basal MOR activation decreases 
basal endocytosis and increases MOR plasma membrane levels.3,8,13,14 
Alternatively, after endocytosis, the antagonists could be increasing the recycling 
of the receptors. Following endocytosis, the MORs can be degraded or recycled 
to the surface, and there is evidence that some opioid ligands, like fentanyl, can 
bias towards the recycling pathway.15 There is also a cAMP hypothesis: recent 
work demonstrated that increases in intracellular [cAMP] coincide with increases 
in protein trafficking16. MOR activation decreases [cAMP], so perhaps decreasing 
basal MOR activity will increase [cAMP] and increase trafficking.17  
This study examines the pharmacological chaperoning hypothesis.18 
Pharmacological chaperoning occurs when a pharmacophore binds to a nascent 
protein and promotes proper folding, thus aiding its exit from the ER.19 
Pharmacological chaperoning participates in therapeutic approaches when sub-
optimal protein levels reach the plasma membrane.19-22 Agonists and antagonists 
are capable of chaperoning in various systems, and several studies show that 
ligands promote trafficking of δ-opioid receptors.23,24  
 Research investigating pharmacological chaperoning has not yet 
examined key early events in MOR surface expression, in part because MORs 
traffic rather efficiently to the plasma membrane. We have therefore investigated 
the MOR[N190K] mutant, which is substantially retained in the ER.25 We 





of this mutant. In previous experiments with nicotinic receptors, pharmacological 
chaperoning produces increases in ERES levels.26,27 We established that Sec24D, 
one of four Sec24 isoforms that can participate in ERES formation, does interact 
with MORs, suggesting that Sec24D shuttles MORs. We used Sec24D-eGFP to 
visualize ERES and observe changes in the fraction of the cytoplasm that ERES 
occupy in response to drug treatment. Heinzer et al. reasoned that increasing the 
size of ERES is a more advantageous strategy for increasing secretory flux than 
increasing the number of ERES, thus measuring the fraction of the cytoplasm 
occupied by ERES is more appropriate than measuring the total number of 
ERES.28 The possibility that antagonists induce supersensitivity by 
pharmacologically chaperoning opioid receptors could suggest innovative 
approaches for opioid abuse disorder.   
4.3 Results 
4.3.1 MOR[N190K] reaches wild-type plasma membrane densities after Ntx or 
naloxone treatment 
In contrast to the other opioid receptor subtypes, MORs are primarily 
localized on the plasma membrane.3 This lack of ER-localized MORs vitiates 
systematic studies of chaperoning. To increase the pool of MORs in the ER, we 
generated the MOR[N190K] mutant 25. This N190K mutation impairs trafficking:  
most MOR[N190K] is retained in the ER. Prior reports state that wild-type plasma 
membrane expression is rescued by treating the MOR[N190K] expressing cells 
with Ntx.25 Here, we generated the MOR[N190K] mutant with mCherry on the C-
terminus to visualize the receptor. After antagonist treatment, we did observe 
fluorescent intensity outlining the cell, suggesting an increase in plasma 






4.3.2 MOR interacts with Sec24D 
There are four Sec24 isoforms, so it is imperative to validate that a specific 
isoform interacts with the MOR. In order to verify that the MOR and Sec24D 
interact with each other, we performed sensitized emission FRET experiments.29 
The donor was eGFP attached to Sec24D and the acceptor was mCherry attached 
to MOR[N190K]. The MOR[N190K] mutant was used to ensure that a large pool 
of receptors would be in the ER, available to interact with Sec24D. As a negative 
control, we used Rab5-eGFP as a donor. Rab5 localizes to early endosomes, thus 
we would not expect Rab5 to interact extensively with the MOR[N190K].30 We 
quantified cFRET, a sensitized emission FRET method that corrects for spectral 
bleed-through from the donor excitation to acceptor emission in the absence of 
FRET (see Methods).  We found that the Sec24D-MOR[N190K] FRET pair results 
in significantly greater cFRET intensity and FRET efficiency than the Rab5-
MOR[N190K] FRET pair (Figure 4.2). These results suggest that the MOR 
interacts with Sec24D. The MOR[N190K]-mCherry + Rab5-eGFP samples serve 
Figure 4.1 MOR[N190K] appears on the plasma membrane after 24 h incubation in 
10 μM Ntx or naloxone. SH-SY5Y cells were transfected with MOR[N190K]-mCherry 
and treated with (A) vehicle, (B) 10 µM Ntx, or (C) 10 µM naloxone for 12 h. The 
vehicle-treated samples show no plasma membrane localization of MOR[N190K]-
mCherry while both the Ntx and naloxone treated cells are outlined with fluorescent 






as an additional negative control to rule out spectral bleed-through from the donor 
excitation wavelength to the acceptor excitation spectrum. 
 
4.3.3 Ntx and naloxone, but not agonists, induce increases in ERES in SH-SY5Y 
cells overexpressing MOR[N190K] 
To observe ERES specifically upregulated due to MOR chaperoning, we 
overexpress the ER-retained MOR mutant, MOR[N190K], in SH-SY5Y cells.25 
First, the percentage of the cytoplasm occupied by ERES was measured in SH-
SY5Y cells transfected with MOR[N190K] and Sec24D-eGFP after 12 h incubation 
Figure 4.2. FRET analysis shows that in living cells, MOR is close to Sec24D. (A) 
Representative images of SH-SY5Y cells expressing Rab5-eGFP, Sec24D-eGFP, 
MOR[N190K]-mCherry, Rab5-eGFP and MOR[N190K]-mCherry, or Sec24D-eGFP 
and MOR[N190K]-mCherry. Left column, samples are excited at 561 nm excitation 
filter and imaged at 610 nm to reveal mCherry. Center column, samples are excited 
with at 488 nm excitation filter and imaged at 510 nm to reveal eGFP. Right column, 
samples are excited at 488 nm excitation filter and imaged at 610 nm to reveal 
sensitized emission. (B1) The cFRET intensities and (B2) FRET efficiency from the 
two FRET samples (Rab5-eGFP and MOR[N190K]-mCherry or Sec24D-eGFP and 
MOR[N190K]-mCherry. P-values are calculated from a Student’s t-test. *, p < 0.05; 






in 10 µM Ntx or naloxone. We chose to analyze the z-stacks to investigate ERES 
levels in the entire cell (Figure 4.3). Both Ntx and naloxone treatments showed a 
significant increase in ERES levels (Figure 4.3). Together, these results suggest 
that the antagonists are increasing ERES levels by binding and chaperoning ER-
localized MORs. In contrast, among the full and partial agonists tested, none 
caused a significant increase in ERES levels (Figure 4.3).  
 
 
Figure 4.3. Representative image of a 3D rendering of the z-stacks obtained for 
ERES analysis. Each slice of the z-stack is 0.1 µm apart. The transparent grey region 
represents the cytoplasm. The opaque structures represent ERES. Each color 
represents a separate ERES. The analysis distinguishes individual ERES within a 
cluster, based on the assumption measurements that the average ERES is 500 nm in 
diameter (Heinzer et al). However, this distinction is not used to calculate the fraction 










































































































































































































































































































































































































































































































































































































































4.3.4 N-methyl-naltrexone does not cause a significant shift in ERES levels 
To test the dependence of antagonist entry into the cytoplasm for ERES 
level increases, we used N-methyl-naltrexone (Me-Ntx), a permanently charged 
derivative of Ntx.31 Me-Ntx crosses the plasma membrane at a substantially lower  
rate than Ntx. Since Me-Ntx will not reach the ER, the pharmacological 
chaperoning hypothesis predicts that Me-Ntx would not induce a rise in ERES 
levels. Indeed, unlike Ntx, Me-Ntx did not cause a significant shift in ERES levels 
in SH-SY5Y cells overexpressing MOR[N190K] (Figure 4.4). These results 
support the hypothesis that the antagonists work in an “inside-out” manner as 
pharmacological chaperones for MORs in the ER.  
 
4.3.5 Observation of ERES upregulation requires 12 h incubation with Ntx 
Next, we tested the temporal dependence of the ERES upregulation event. 
To observe the increase in MORs on the surface, it typically requires ~24 h 




































Figure 4.5. Ntx, but not agonists, increase ERES levels in SH-
SY5Y cells despite abolition of the S375 phosphorylation site. 
SH-SY5Y cells were transfected with MOR[N190K][S375A] and 
Sec24D-eGFP. p-values are calculated from an ANOVA and 






incubation with the antagonist to reach peak MOR surface densities.32 We also 
tested 4 h incubations with Ntx. The significant shift in ERES levels did not occur 
after 4 h but did occur after 12 h (Figure 4.4). These results suggest that 
approximately 12 h is required for increased ERES levels to be observed. 
 
4.3.6 The lack of significant chaperoning by agonists is not due to phosphorylation 
at S375 
When MORs become activated, they undergo a series of phosphorylation 
events before arrestin recruitment and endocytosis.33 One of the key residues for 
phosphorylation is S375: point mutations at this site are most effective for reducing 
receptor internalization.34-36 If antagonists increase ERES levels via preventing 
phosphorylation, then perhaps using a mutant that cannot be phosphorylated at 
S375 might allow agonists to increase ERES levels. Ntx continues to induce a rise 
in ERES levels in SH-SY5Y cells overexpressing MOR[N190K][S375A], providing 
a positive control for these experiments (Figure 4.5). However, morphine and 
fentanyl do not significantly increase ERES levels in SH-SY5Y cells 
overexpressing MOR[N190K][S375A](Figure 4.5). While it is not clear whether 
S375 is becoming phosphorylated by agonists in the ER, mutating this residue to 
alanine does not enhance the chaperoning effects of agonists.  
 
4.3.7 Ntx does not induce a rise in [cAMP] 
An increase in intracellular [cAMP] occurs when cargo export increases in 
fibroblasts or HeLa cells.16 It is not known whether there is an increase in [cAMP] 
with Ntx treatment without prior MOR activation. Here we tested whether Ntx 





competition assay was used to measure relative concentrations of cAMP in SH-
SY5Y cells transfected with MOR[N190K] after 12 h incubation with 10 µM Ntx, 15 
min incubation with 10 µM forskolin (positive control for increases in [cAMP]), or 
vehicle. Our results suggest that Ntx does not increase [cAMP] (Figure 4.6). This 
is not surprising because the most likely way for Ntx to increase [cAMP] is by 
further inhibiting the MOR below its basal activity. The activity of MORs requires 
activation with agonists; thus observing a significant increase in [cAMP] by further 
inhibiting MORs is unlikely.37,38 Since cAMP concentration changes have been 
ruled out as the cause of MOR upregulation, the chaperoning hypothesis remains 
the leading explanation for how Ntx and naloxone increase ERES levels. 
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Figure 4.6 [cAMP] levels do not change in cells treated with Ntx. SH-SY5Y cells were 
transfected with MOR[N190K] as in ERES imaging experiments. These cells were 
then treated with either 10 µM Ntx for 12 h, vehicle for 12 h followed by 10 µM 
forskolin for 15 min, or vehicle for 12 h. Forskolin-treated cells serve as a positive 
control for [cAMP] increases. Measurements for [cAMP] were normalized to vehicle-
treated samples (represented by the dotted line). These results show that [cAMP] 
increases in forskolin-treated but not in NTx-treated cells, relative to vehicle-treated 
samples.  p-values are calculated from an unpaired Student’s t-test where p < 0.05 is 






4.3.8 Ntx pharmacological chaperoning depends on COPI 
Coat protein I (COPI) vesicles 39-41 are retrotransport cargo from the Golgi to the 
ER to aid in sorting and protein quality control.42 COPI vesicles are composed of 
seven core subunits, α-COP, β’-COP, ε-COP, βCOP, δ-COP, γ-COP, and ζ-COP 
and are thus distinct from ERES. Prior work in our lab and others have 
demonstrated that COPI vesicles can play a role in pharmacological 
chaperoning.18,43 Here, we find a similar dependence as Ntx and naloxone no 
longer increase ERES levels if the cells are co-treated with brefeldin A (BFA), a 
COPI inhibitor (Figure 4.4, purple).18,32,44 These results suggest that some of the 
ERES observed in the non-BFA treated cells have already traveled to the Golgi. 
This suggests that MORs must undergo multiple rounds of ER-Golgi trafficking 
before final maturation and presentation on the plasma membrane. This retrograde 
trafficking dependence is not uncommon for some cargos, and it appears that the 
MORs also depend on some ER-Golgi cycling before they are completely ready to 
go to the plasma membrane. 
4.4 Discussion  
Although efforts continue to reduce pain by actions on non-MOR targets 
such as the voltage-gated sodium channels and some nicotinic receptors, at 
present the MOR continues to be the primary target for analgesic drugs.45,46 MOR 
trafficking is important to the development of opioid use disorder. If we can 
understand MOR trafficking and manipulate MOR surface densities in predictable 
ways, we may better treat opioid use disorder. Until now, there have been no 
studies done on ERES and MORs. 
Here we show that, for a mutant MOR that builds to observable levels in 





occupied by ERES. This is likely an early event in the pathway that results in 
increased opioid receptor surface densities and supersensitivity (Figure 4.4). By 
demonstrating that this adverse effect of antagonist treatment is manifested 
through ERES, we show that ERES can be considered a component in opioid use 
disorder. 
Many agonists cause some endocytosis, but whether these drugs also 
cause chaperoning is not clear. We find that morphine, fentanyl, buprenorphine, 
and methadone do not cause a significant change in ERES levels. Our work 
suggests that the conformation induced by these agonists is less favorable for 
chaperoning than the conformation induced by the antagonists. In one hypothesis, 
this may be due to the lack of S375 phosphorylation when an antagonist is bound.36 
To test this, we made MOR[N190K][S375A], a MOR mutant that is highly-ER 
retained and could not be phosphorylated at S375. Despite the inability to 
phosphorylate S375, ERES levels did not significantly change using this mutant 
after 12 h incubation in 10 µM morphine or fentanyl (Figure 4.5).  
We ruled out that the increases in ERES arise from increases in [cAMP] by 
measuring [cAMP] in MOR[N190K]-overexpressing SH-SY5Y cell lysates after 
incubation in Ntx, vehicle, or forskolin using a competitive ELISA assay. We 
overexpress MOR[N190K] to most closely replicate cells used in the imaging 
experiments. SH-SY5Y cells endogenously express the MOR, thus there will be 
MORs exhibiting basal activity at the plasma membrane that could be reduced by 
antagonist exposure.47 Despite decreasing the basal activity of the MORs, we did 
not observe a significant change in [cAMP] in cells treated with Ntx (Figure 4.6). 
Since [cAMP] rises are no longer a viable reason for the increase in ERES levels, 





Our work does not challenge the prevailing view that, for the wild type MOR, 
agonists affect MOR via endocytosis at the plasma membrane—a much later stage 
than studied here.48 The lack of substantial chaperoning by agonists is consistent 
with prior observations that several of the key steps in ERES formation could well 
be suppressed by the effects of MOR activation (such as increases in [cAMP]).16,49 
The endocytosed MOR plays a role in the cellular response to membrane-
permeant opioids since the MOR can signal within recycling endosomes; in 
addition, MOR may also signal within the Golgi. 50 Fentanyl increases the recycling 
of MORs after endocytosis.15 This observation, along with our results that 
antagonists can control trafficking from the ER to the Golgi, emphasizes how the 
earlier mechanisms that deliver MORs to the plasma membrane from the ER are 
regulated differently than the later mechanisms that traffic MORs from 
endosomes.15 Pathways to the plasma membrane vary among MORs, and one 
may target one route over the other.  
These results also give insight into how the mutant MOR matures in the ER 
and Golgi. The lack of ERES increases with COPI inhibition suggests some 
recycling between the ER and the Golgi. This observation is consistent with the 
~24 hour incubation with naltrexone before observing increased MOR plasma 
membrane levels.32 We also observe some time dependence with our ERES 
experiments (Figure 4.4). We hypothesize that after 4 hours, the mutant MOR has 
not had an opportunity to enter the Golgi-ER pathway, and only after 12 hours do 
we observe this transition as an increase in ERES levels. Furthermore, these COPI 
experiments are consistent with prior reports demonstrating the importance of 





Our results provide key information regarding MOR trafficking. We find that 
the antagonists can increase ERES levels, showing that in this case ERES exit 
events are rate-limiting for downstream MOR plasma membrane densities. 
Meanwhile, agonists do not increase ERES levels, consistent with their inability to 
increase MOR plasma membrane densities. Pharmacological chaperoning starts 
at the ER in many cases, and our work provides further evidence that Ntx and 
naloxone are pharmacological chaperones for the MOR.  
Our work also continues to make a case for pharmacological chaperoning 
as an important part of a drug’s efficacy profile.22 This part of “inside-out 
pharmacology” involves using ligands to increase the trafficking of receptors.51  
Our study applies only to the rare MOR[N190K] mutant; in pilot 
experiments, we found neither upregulation nor effects on ERES levels with wild 
type MOR. This limits our ability to explain the mechanism of 
upregulation/supersensitivity of MOR found in studies on intact animals with WT 
MORs treated with antagonists.11,52,53 Superresolution experiments like those 
described here cannot yet be applied to native neurons of intact neural pathways.  
One would need to invoke additional, unknown aspects of chaperoning to 
generalize its usefulness as a mechanism for upregulation / supersensitivity. This 
point resembles the uncertainties about mechanisms that allow nicotine to 
upregulate nicotinic receptors of only some cells types and only at some 
subcellular regions.51 
 To the extent that pharmacological chaperoning does govern upregulation 
/ supersensitivity by naltrexone, we note that Me-Ntx is FDA-approved to suppress 
opioid-induced constipation (OIC) when opioids are used for chronic noncancer 





membrane-impermeant antagonists, unlike membrane-permeant antagonists 
such as naltrexone and naloxone, are unlikely to cause upregulation / 
supersensitivity. This difference would arise from the same mechanism that allows 
Me-Ntx to block peripheral but not CNS MOR: it does not permeate across 
membranes.54 Perhaps Me-Ntx deserves wider use for its approved indications. 
4.5 Materials and Methods 
4.5.1 Reagents  
All reagents were obtained from Sigma-Aldrich (St. Louis, MO). The MOR 
plasmid was a gift from Dr. Brigitte Kieffer. The MOR-mCherry plasmid was 
purchased from VectorBuilder (The vector ID is VB181109-1086uuu, which can be 
used to retrieve detailed information about the vector on vectorbuilder.com). The 
eGFP-Sec24D plasmid was used as previously described. All other mutants were 
generated using site-directed mutagenesis using standard protocols.  
 
4.5.2 SH-SY5Y cell culture and transfection  
SH-SY5Y cells were purchased from the ATCC® (CRL-2266TM). Cells were 
cultured according to the protocols specified by the ATCC, except Opti-Mem was 
used instead of EMEM/F12. Cells were cultured in 35 mm dishes with a glass 
coverslip on the bottom and allowed to reach 90% confluency before transfection. 
Transfection was carried out using LipofectamineTM 3000 (Thermo Fisher) using 
the standard protocols. Typical DNA loads were between 0.5 and 1.0 µg per dish. 
Transfection media was replaced 24 h post-transfection with growth media. Drugs 
were added to the cell media to give a total drug concentration of 10 µM, 12 h 
before imaging. Before imaging, the cells were washed once with phosphate-






4.5.3 Z-stack confocal microscopy  
The Zeiss LSM 880 with “Fast Airyscan” was used. The pixel dwell time 
was ~ 0.2 µs. Each slice was taken 0.1 µm from the previous one. All images and 
z-stacks were processed using Airyscan processing in the Zen Blue software 
package (Zeiss).   
 
4.5.4 Sensitized Emission Förster resonance energy transfer (FRET) 
FRET experiments were performed following a procedures described by Elder and 
co-workers 29 and previously used in this lab 55,56 to calculate sensitized emission 
FRET with corrections for donor bleed-through into the acceptor channel, and vice 
versa, SH-SY5Y cells were transfected with either Sec24D-eGFP, Rab5-eGFP, or 
MOR[N190K]-mCherry to establish the acceptor emission ratio (AER) or donor 








                                                           (2) 
where IAD is mCherry fluorescence intensity in the mCherry channel with 488 nm 
excitation, IAA is mCherry fluorescence intensity in the mCherry channel with 561 
nm excitation, IDA is eGFP fluorescence intensity in the mCherry channel with 488 
nm excitation, and IDD is eGFP fluorescence intensity in the eGFP channel using 
488 nm excitation. The FRET samples were transfected with MOR[N190K]-
mCherry and Sec24D-eGFP or Rab5-eGFP. Using the AER and DER values 
calculated in the samples expressing one fluorescent protein, the following 






 𝑐𝐹𝑅𝐸𝑇 = 𝐼𝐷𝐴 − (𝐷𝐸𝑅)(𝐼𝐷𝐷) − (𝐴𝐸𝑅)(𝐼𝐴𝐴)                                        (3) 
where IDA, IDD, and IAA are measured in the FRET sample using the same 
parameters as those used in the samples to obtain the AER and DER. Using the 
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All five samples were imaged on the same day on the same microscope.  
 
4.5.5 Image Analysis 
All 2D image analysis was performed using FIJI. To determine the 
threshold to designate ERES, the 2D image was smoothed three times in FIJI and 
an ROI was drawn around the entire cell. The top 5% of the most intense pixels 
that constitute a puncta larger than 0.1 µm2 in the ROI were marked as ERES. This 
same intensity threshold was used to designate ERES in the 3D images which 
were analyzed in Imaris (Bitplane). Among the various metrics presented by 
Imaris, we emphasize the fraction of cytoplasmic volume occupied by ERES, 
because this volume-integrated metric is relatively insensitive to assumptions 
about size, shape, and number of individual particles.  
 
4.5.6 Competitive ELISA for [cAMP] measurement 
SH-SY5Y cells were grown to 90% confluency and transfected with 
MOR[N190K]. The cells were lysed with 0.1 M HCl 48 h. post-transfection and after 
the appropriate drug treatment (12 h. with 10 µM Ntx, 15 min. with 10 µM forskolin 
(positive control for [cAMP] upregulation), or vehicle). Lysates were centrifuged at 





insoluble debris. The supernatant was used for the remainder of the procedure as 
described by the protocol provided with the cAMP Assay Kit (Abcam, ab65355).  
 
4.5.7 Statistical Analysis   
All results are presented as mean ± S.E.M. and all statistical analyses were 
performed using GraphPad Prism. Statistical significance was determined by an 
unpaired Student’s t-test (in comparisons between two samples) or an ANOVA 
with a post-hoc Tukey test (in comparisons with more than two samples). In 
comparisons where the p-value < 0.05, these differences were considered 
significant. 
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Chapter 5: Agonist-induced µ-opioid receptor endocytosis 
is dependent on phosphorylation at the C-terminus 
5.1 Abstract 
The opioid crisis is largely a result of the addictive nature of opioids. The 
relatively rapid initiation of dependence and tolerance to opioids results from 
various actions, one of which being µ-opioid receptor (MOR) endocytosis following 
activation. Activation will usually lead to various phosphorylation events on the C-
terminus, and some of these are important for receptor internalization. 
Experiments to determine the dependence on C-terminal phosphorylation for 
endocytosis were done using DAMGO binding assays to determine the amount of 
MORs on the plasma membrane. Here, we decide to expand on some of these 
measurements using an endosome localization assay following morphine and 
fentanyl treatment. Currently, the data regarding morphine-induced internalization 
is conflicted, and precise experiments regarding fentanyl and the C-terminal’s 
phosphorylation status are lacking. Here, we find that both morphine and fentanyl 
induce increases in MOR-endosome colocalization, suggesting that both drugs 
increase endocytosis. We do not observe MOR-endosome colocalization 
increases after morphine treatment if the S375 residue is mutated to alanine. 
These results are similar to what has been observed in other labs where the 
MOR[S375A] mutant did not undergo endocytosis following DAMGO treatment. 
We do not observe MOR-endosome colocalization increases after fentanyl 
treatment if most C-terminal phosphorylation sites (T354, S355, S356, T357, S363, 
S364, T370, S375, T376, and T379) are mutated to alanine. These results 
continue the narrative that C-terminal phosphorylation is important for developing 




The previous chapter delved into the supersensitivity induced by opioid 
antagonists that resulted from increases in the MOR density on the plasma 
membrane. The inverse is true for many agonists where they induce internalization 
and decrease the MOR plasma membrane density.1-8 Unfortunately, unlike 
pharmacological chaperoning, which mostly relies on the protein and the small 
molecule, MOR internalization involves many factors. The opioid receptors are G-
protein coupled receptors (GPCR), and as such, they will interact with many 
different cytosolic proteins.9 The two proteins that get the most attention are the β-
arrestins and the G proteins.10 These protein classes have been studied 
extensively because the β-arrestins are generally responsible for most of the 
negative effects of opioid use (respiratory depression, tolerance, and receptor 
desensitization) while G-protein coupling is associated with the desired analgesic 
effects.11 Some agonists will induce more β-arrestin coupling than G-protein 
coupling or vice versa; the preference between one or the other is the foundation 
of biased agonism.12,13 Biased agonists are one of the most popular directions 
scientists have taken to find safer analgesics. Unfortunately, morphine and other 
opioids remain the “gold standard” for pain relief medications.14-16 Unfortunately, 
with over 30% of all Americans suffering from some form of chronic pain, opioids 
are one of the most prescribed substances, and along with the ease of which to 
acquire illicit opioids, there is an overabundance of opioids in the public that make 
the opioid crisis a major problem.17 
One can say that the chief issue with opioids is the downstream effects of 
β-arrestin binding. In many GPCRs, β-arrestin follows after receptor 
phosphorylation.18 While the crucial phosphorylation sites will vary between 
86 
 
different GPCRs, the key phosphorylation sites in the MOR for receptor 
internalization are in the C-terminus (Figure 5.1).4,19,20 The site that has gotten 
special interest is the S375 site. Studies show that S375 is the first residue 
phosphorylated, it will be selectively phosphorylated by morphine, and prevention 
of S375 phosphorylation will inhibit DAMGO-induced endocytosis.20-22 In terms of 
further phosphorylation, there is some debate on what sites are only 
phosphorylated in the presence of agonists.23-25 Nevertheless, there is agreement 
that there is a strong link between phosphorylation and internalization. 
Here we decide to expand on these studies by conducting fluorescence-
based experiments investigating how phosphorylation at the C-terminus influences 
morphine- and fentanyl-induced endocytosis. Our experiments will measure the 
colocalization between the MOR and the early endosome. As opposed to binding 
assays, this measurement will specifically look at endocytosis and will not depend 
on potential complications from various states of the MOR that may inhibit DAMGO 
binding. For example, prolonged exposure to agonists can induce desensitization, 
which can change the binding properties of the receptor.26 Since we are only 
dependent on fluorescence, the conformation of the MOR is not important in our 
assay. Further, our assay is specific for endocytosis, while binding assays examine 
general decreases in the MOR plasma membrane density. We found that both 




Figure 5.1 C-terminal sequence of the human MOR according to UNIPROT. 





following a 30 minute treatment compared to untreated cells. However, there were 
no morphine-induced increases in MOR-early endosome colocalization if there 
was an S375A mutation. Conversely, we needed to mutate T354, S355, S356, 
T357, S363, S364, T370, S375, T376, and T379 to alanine to prevent fentanyl-
induced increases in MOR-early endosome colocalization. These results continue 
to support the importance of C-terminal phosphorylation to endocytosis. 
5.3 Results and Discussion 
5.3.1 Morphine and fentanyl induce endocytosis of MORs in SH-SY5Y cells 
While most researchers are convinced that fentanyl will induce 
endocytosis, morphine-induced endocytosis appears very dependent on the 
system used.1,5,27,28 Here, we overexpress the MOR-mCherry via transfection of 
cDNA. We also used CellLightTM Early Endosome GFP to visualize early 
endosomes. We used a Zeiss LSM 880 with “Fast Airyscan” to image the MOR-
mCherry and CellLightTM Early Endosome GFP. The Pearson’s correlation 
coefficient was calculated using a FIJI plug-in. We acknowledge that there are 
certain advantages and disadvantages to this method, but we are confident that 
these experiments will shed light on how the MOR C-terminus influences agonist-
induced endocytosis. We also decided to use equally efficacious doses of fentanyl 
(0.2 µM) and morphine (10 µM) instead of equal molar concentrations of the 
agonists.29 
Here, we find that both fentanyl and morphine will increase the 
colocalization of MORs and early endosomes (Figure 5.2). Both of these 
observations agree with results from other labs and suggest that our assay can 
detect increases in agonist-induced endocytosis. 
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5.3.2 Fentanyl will, but morphine will not increase endocytosis of MOR[S375A] 
Next, we decided to start mutating some of the C-terminal phosphorylation 
sites to alanine so that phosphorylation would become impossible. This strategy 
has been used extensively for similar purposes and the receptors remained 
functional.22,30 We start with arguably the most important phosphorylation site, 
S375. Compared to vehicle-treated samples, we find that morphine does not 
increase endocytosis, but fentanyl still does (Figure 5.3). These results are 
consistent with observations that morphine only phosphorylates S375 and that 
phosphorylation is important for MOR endocytosis.11,22,24 Meanwhile, we know that 
fentanyl will phosphorylate sites other than S375, which appears sufficient to 
recruit β-arrestin and induce endocytosis.21 
Next, we tested the single mutant, MOR[T370A], to see if morphine 
depends specifically on S375 phosphorylation. Here, we find that both morphine 




































and fentanyl will increase endocytosis of MOR[T370A] (Figure 5.4). These results 
suggest that the T370 site is not as critical to morphine’s ability to induce 
endocytosis as the S375 site is. Indeed, this is consistent with other reports that 
emphasize that the S375 site is the only one phosphorylated by morphine. 
 
5.3.3 Inhibiting fentanyl-induced endocytosis requires the abolition of several C-
terminal phosphorylation sites 
We next progressively mutated phosphorylation sites to alanine and 
continued to test both fentanyl- and morphine-induced endocytosis. Significance 
was determined by comparing to untreated samples using a Student’s t-test. 
Consistent with S375 residue’s importance to morphine-induced MOR 
endocytosis, all subsequent MOR mutants were not endocytosed significantly 
more when treated with morphine over the vehicle (Figure 5.5). In contrast, we 
observed increases in endocytosis after fentanyl treatment for all mutants except 
for when we mutated T354, S355, S356, T357, S363, S364, T370, S375, T376, 
Figure 5.3 The S375A mutation prevents morphine-induced endocytosis, but not 




































and T379 to alanine. These results suggest that fentanyl-induced endocytosis will 
not occur if most of the C-terminal serine and threonine residues cannot be 
phosphorylated. 
5.4 Conclusions 
MOR endocytosis plays a critical role in developing tolerance to 
opioids.2,30,31 The field has made tremendous progress in this area, where we are 
quite sure that β-arrestin coupling to the MOR promotes endocytosis.6,7,12,32 
Presently, we are still not sure what some of the most important opioids do 
regarding endocytosis. Here, we expand on these studies by observing the 
colocalization of MORs and early endosomes following morphine or fentanyl 
treatment. Consistent with other experiments, our assay suggests that morphine 
and fentanyl induce endocytosis in SH-SY5Y cells expressing MOR-mCherry.5,8,27 
We no longer observe morphine-induced endocytosis if the S375 residue is 
mutated to alanine, but we need to mutate T354, S355, S356, T357, S363, S364, 





































T370, S375, T376, and T379 to alanine in order to inhibit fentanyl-induced 
endocytosis. 
Future efforts in this study will require orthogonal experiments to validate our 
microscopy observation. Since this is a novel means of measuring MOR 
endocytosis, these orthogonal experiments are critical. We did some preliminary 
immunoblots to evaluate MOR levels, but the results are inconclusive. Further 
attempts may turn to binding assays or other biochemical experiments to evaluate 
MOR density on the plasma membranes. 
 
Figure 5.5 MOR mutants and their Pearson’s correlation co-efficients with early 
endosomes after agonist treatment. None of the mutants here were endocytosed 
significantly more after morphine treatment. Only the S363A, S375A, T370A, T376A, 
T379A, S364A, TSS354-357AAA mutants did not have increased endocytosis after 
fentanyl treatment.  
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5.5 Materials and Methods 
5.5.1 Reagents, materials, and plasmids 
All reagents were obtained from Sigma-Aldrich (St. Louis, MO). The MOR 
plasmid was a gift from Dr. Brigitte Kieffer. The MOR-mCherry plasmid was 
purchased from VectorBuilder (the vector ID is VB181109-1086uuu, which can be 
used to retrieve detailed information about the vector on vectorbuilder.com). 
Mutations were made using a QuikChange protocol (Stratagene). CellLightTM Early 
Endosome GFP was purchased from ThermoFisher. 
 
5.5.2 SH-SY5Y cell culture and transfection 
SH-SY5Y cells were purchased from the ATCC® (CRL-2266TM). Cells were 
cultured according to the protocols specified by the ATCC, except Opti-Mem was 
used instead of EMEM/F12. Cells were cultured in MatTek® 1.5 coverslip-14C-35 
mm glass bottom dishes and allowed to reach 90% confluency before transfection. 
Transfection was carried out using LipofectamineTM 3000 (Thermo Fisher) using 
the standard protocols. Typical DNA loads were between 0.5 and 1.0 µg per dish. 
Transfection media was replaced 24 hours post-transfection with 3 mL of growth 
media and 2 µL of CellLightTM Early Endosome GFP. Drugs were added to the cell 
media to give a total drug concentration of 10 µM for morphine or 0.2 µM for 
fentanyl, 30 minutes before imaging. Before imaging, the cells were washed once 







5.5.3 Imaging and analysis 
Imaging was performed on a Zeiss LSM 880 with “Fast Airyscan.” Fast 
Airyscan improves the signal-to-noise ratio by incorporating the photons that 
traditionally get rejected by the confocal pinhole to help reconstitute the image. 
Image dimensions varied to ensure ideal “Fast Airyscan” conditions. Pixel dwell 
time was ~2 µs. 
The top 5% most intense pixels in each channel were used to calculate the 
Pearson’s correlation coefficient. The calculation was performed using the “Coloc 
2” plug-in in FIJI. The “Pearson’s R Values (no threshold)” were recorded and used 
for further analysis. The “Pearson’s R Values” were compiled into a GraphPad 
Prism file for statistical analysis. A Student’s t-test was used to compare each drug-
treated sample to the untreated control. Any pair where p < 0.05 was considered 
to be significantly different. 
5.6 References 
1 Sternini, C. et al. Agonist-selective endocytosis of μ opioid receptor by 
neurons in vivo. PNAS 93, 9241-9246 (1996). 
2 Whistler, J. L., Chuang, H. H., Chu, P., Jan, L. Y. & von Zastrow, M. 
Functional dissociation of µ opioid receptor signaling and endocytosis: 
implications for the biology of opiate tolerance and addiction. Neuron 23, 
737-746, doi:10.1016/s0896-6273(01)80032-5 (1999). 
3 Finn, A. K. & Whistler, J. L. Endocytosis of the µ opioid receptor reduces 
tolerance and a cellular hallmark of opiate withdrawal. Neuron 32, 829-839, 
doi:10.1016/s0896-6273(01)00517-7 (2001). 
4 Koch, T. et al. C-terminal splice variants of the mouse μ-opioid receptor 
differ in morphine-induced internalization and receptor resensitization. J. 
Biol. Chem. 276, 31408-31414, doi:10.1074/jbc.M100305200 (2001). 
5 Minnis, J. G. et al. Ligand-induced μ opioid receptor endocytosis and 
recycling in enteric neurons. Neuroscience 119, 33-42, doi:10.1016/S0306-
4522(03)00135-0 (2003). 
6 Martini, L. & Whistler, J. L. The role of µ opioid receptor desensitization and 
endocytosis in morphine tolerance and dependence. Curr. Opin. Neurobiol. 
17, 556-564, doi:10.1016/j.conb.2007.10.004 (2007). 
7 Williams, J. T. et al. Regulation of µ-opioid receptors: Desensitization, 
phosphorylation, internalization, and tolerance. Pharmacol. Rev. 65, 223-
254, doi:10.1124/pr.112.005942 (2013). 
94 
 
8 Anselmi, L., Jaramillo, I., Palacios, M., Huynh, J. & Sternini, C. Ligand-
induced opioid receptor internalization in enteric neurons following chronic 
treatment with the opiate fentanyl. J. Neurosci. Res. 91, 854-860, 
doi:10.1002/jnr.23214 (2013). 
9 Jean-Alphonse, F. & Hanyaloglu, A. C. Regulation of GPCR signal 
networks via membrane trafficking. Molecular and Cellular Endocrinology 
331, 205-214, doi:10.1016/j.mce.2010.07.010 (2011). 
10 Schmid, C. L. et al. Bias factor and therapeutic window correlate to predict 
safer opioid analgesics. Cell 171, 1165-1175.e1113, 
doi:10.1016/j.cell.2017.10.035 (2017). 
11 Bohn, L. M., Gainetdinov, R. R., Lin, F. T., Lefkowitz, R. J. & Caron, M. G. 
µ -opioid receptor desensitization by beta-arrestin-2 determines morphine 
tolerance but not dependence. Nature 408, 720-723, 
doi:10.1038/35047086 (2000). 
12 Molinari, P. et al. Morphine-like opiates selectively antagonize receptor-
arrestin interactions. J. Biol. Chem. 285, 12522-12535, 
doi:10.1074/jbc.M109.059410 (2010). 
13 Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A. & Novick, S. 
A simple method for quantifying functional selectivity and agonist bias. ACS 
Chem. Neurosci. 3, 193-203, doi:10.1021/cn200111m (2012). 
14 Gabriel, R. A. et al. State of the art opioid-sparing strategies for post-
operative pain in adult surgical patients. Expert Opin. Pharmacother. 20, 
949-961, doi:10.1080/14656566.2019.1583743 (2019). 
15 Kaye, A. D. et al. New opioid receptor modulators and agonists. Best 
Practice & Research. Clinical Anaesthesiology 32, 125-136, 
doi:10.1016/j.bpa.2018.06.009 (2018). 
16 Livingston, K. E. & Traynor, J. R. Disruption of the Na+ ion binding site as 
a mechanism for positive allosteric modulation of the µ-opioid receptor. 
PNAS 111, 18369-18374, doi:10.1073/pnas.1415013111 (2014). 
17 Volkow, N. D. & McLellan, A. T. Opioid abuse in chronic pain — 
misconceptions and mitigation strategies. NEJM 374, 1253-1263, 
doi:10.1056/NEJMra1507771 (2016). 
18 Mayer, D. et al. Distinct G protein-coupled receptor phosphorylation motifs 
modulate arrestin affinity and activation and global conformation. Nat. 
Commun. 10, 1261, doi:10.1038/s41467-019-09204-y (2019). 
19 Yu, Y. K. et al. µ opioid receptor phosphorylation, desensitization, and 
ligand efficacy. J. Biol. Chem. 272, 28869-28874, 
doi:10.1074/jbc.272.46.28869 (1997). 
20 El Kouhen, R. et al. Phosphorylation of Ser363, Thr370, and Ser375 
residues within the carboxyl tail differentially regulates μ-opioid receptor 
internalization. J. Biol. Chem. 276, 12774-12780, 
doi:10.1074/jbc.M009571200 (2001). 
21 Just, S. et al. Differentiation of opioid drug effects by hierarchical multi-site 
phosphorylation. Mol. Pharmacol. 83, 633-639, 
doi:10.1124/mol.112.082875 (2013). 
22 Grecksch, G. et al. Analgesic tolerance to high-efficacy agonists but not to 
morphine is diminished in phosphorylation-deficient S375A μ-opioid 




23 Lau, E. K. et al. Quantitative encoding of the effect of a partial agonist on 
individual opioid receptors by multisite phosphorylation and threshold 
detection. Sci. Signal. 4, 12, doi:10.1126/scisignal.2001748 (2011). 
24 Doll, C. et al. Deciphering µ-opioid receptor phosphorylation and 
dephosphorylation in HEK293 cells. Br. J. Pharmacol. 167, 1259-1270, 
doi:10.1111/j.1476-5381.2012.02080.x (2012). 
25 Miess, E. et al. Multisite phosphorylation is required for sustained 
interaction with GRKs and arrestins during rapid µ-opioid receptor 
desensitization. Sci. Signal. 11, 15, doi:10.1126/scisignal.aas9609 (2018). 
26 Shahoei, R. & Tajkhorshid, E. Menthol binding to the human α4β2 nicotinic 
acetylcholine receptor, facilitated by its strong partitioning in membrane. 
The Journal of Physical Chemistry B, doi:10.1021/acs.jpcb.9b10092 
(2020). 
27 Zadina, J. E., Chang, S. L., Ge, L. J. & Kastin, A. J. µ opiate receptor down-
regulation by morphine and up-regulation by naloxone in SH-SY5Y human 
neuroblastoma cells. Journal of Pharmacology and Experimental 
Therapeutics 265, 254 (1993). 
28 Keith, D. E. et al. Morphine activates opioid receptors without causing their 
rapid internalization. The Journal of Biological Chemistry 271, 19021-
19024, doi:10.1074/jbc.271.32.19021 (1996). 
29 Chen, J. C., Smith, E. R., Cahill, M., Cohen, R. & Fishman, J. B. The opioid 
receptor binding of dezocine, morphine, fentanyl, butorphanol and 
nalbuphine. Life Sci. 52, 389-396, doi:10.1016/0024-3205(93)90152-s 
(1993). 
30 Grecksch, G. et al. Development of tolerance and sensitization to different 
opioid agonists in rats. Psychopharmacology 186, 177-184, 
doi:10.1007/s00213-006-0365-8 (2006). 
31 Dang, V. C. & Christie, M. J. Mechanisms of rapid opioid receptor 
desensitization, resensitization and tolerance in brain neurons. Br. J. 
Pharmacol. 165, 1704-1716, doi:10.1111/j.1476-5381.2011.01482.x 
(2012). 
32 Weinberg, Z. Y., Zajac, A. S., Phan, T., Shiwarski, D. J. & Puthenveedu, 
M. A. Sequence-specific regulation of endocytic lifetimes modulates 
arrestin-mediated signaling at the µ opioid receptor. Mol. Pharmacol. 91, 






Chapter 6: Regulation of epithelial sodium channel activity 
by SARS-CoV-1 and SARS-CoV-2 proteins 
*This chapter is adapted from: Stephen N. Grant and Henry A. Lester. 
Regulation of epithelial sodium channel activity by SARS-CoV-1 and 
SARS-CoV-2 proteins Biophysical Journal, 2021. 
6.1 Abstract 
Severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 (SARS-
CoV-2), which causes the coronavirus disease 2019 (COVID-19), encodes several 
proteins whose roles are poorly understood. We tested their ability either to directly 
form plasma membrane ion channels or to change the functions of two mammalian 
plasma membrane ion channels, the epithelial sodium channel (ENaC) and the 
α3β4 nicotinic acetylcholine receptor (nAChR). In mRNA-injected Xenopus 
oocytes, none of nine SARS-CoV-2 proteins or two SARS-CoV-1 proteins 
produced conductances, nor did co-injection of several combinations.  
Immunoblots for ORF8, spike (S), and envelope (E) proteins revealed that the 
proteins are expressed at appropriate molecular weights. In experiments on co-
expression with ENaC, three tested SARS proteins (SARS-CoV-1 E, SARS-CoV-
2 E, and SARS-CoV-2 S) markedly decrease ENaC currents. SARS-CoV-1 S 
protein decreases ENaC currents modestly. Coexpressing the E proteins, but not 
the S proteins, with α3β4 nAChRs significantly reduces acetylcholine-induced 
currents. ENaC inhibition does not occur if the SARS-CoV protein mRNAs are 
injected 24 h after the ENaC mRNAs, suggesting that SARS-CoV proteins affect 
early step(s) in functional expression of channel proteins. Consistent with the 
hypothesis that the SARS-CoV-2 S protein-induced ENaC inhibition involves 
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competition for available protease, mutating the furin cleavage site in SARS-CoV-
2 S protein partially relieves inhibition of ENaC currents. Extending previous 
suggestions that SARS proteins affect ENaC currents via protein kinase C (PKC) 
activation, PKC activation via phorbol 12-myristate 13-acetate (PMA) decreases 
ENaC and α3β4 activity. PMA application reduced membrane capacitance ~ 5%, 
presumably via increased endocytosis, but this decrease is much smaller than the 
SARS proteins’ effects on conductances. Also, incubating oocytes in Gö-6976, a 
PKCα and PKCβ inhibitor, did not alter E or S protein-induced channel inhibition.  
We conclude that SARS-CoV-1 and SARS-CoV-2 proteins alter the function of 
human plasma membrane channels, via incompletely understood mechanisms. 
These interactions may play a role in COVID-19 pathophysiology. 
6.2 Introduction 
The coronavirus disease 2019 (COVID-19) has caused a massive global 
public health crisis. As of April 19, 2021, over 140 million people have been 
infected and over three million lives have been lost to COVID-19, according to the 
Johns Hopkins Coronavirus Resource Center. The pandemic has spurred drastic 
changes throughout the world in every part of life. Understanding this virus gives 
the global community its best chance to return to relatively standard practices. 
However, much like the pandemic it elicited, SARS-CoV-2 is an unprecedented 
virus that requires study from various approaches. 
We sought to contribute to COVID-19 research by systematically studying 
membrane-relevant SARS-CoV-2 proteins, both by themselves and in various 
combinations with host proteins, and comparing homologous proteins from SARS-
CoV-1 and SARS-CoV-2. Plasma membrane viroporins are important for many 
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viruses,1-5 and we tested for their presence in SARS-CoV-2 by expressing SARS-
CoV-1 and SARS-CoV-2 proteins in Xenopus oocytes. 
It is important to understand how the various proteins encoded by SARS-
CoV-2 interact with endogenous human proteins.2,6,7 SARS-CoV-2 must interact 
with host proteins to replicate.8 These interactions begin when the SARS-CoV-2 S 
protein binds to the human angiotensin-converting enzyme 2 (ACE2) protein; this 
interaction leads to viral entry.9-11 Many subsequent interactions have been studied 
between SARS-CoV-2 and human proteins. Studies using mass spectrometry and 
in silico methods identified many protein-protein interactions between SARS-CoV-
2 and humans.7,12 Additionally, researchers have looked to work done on SARS-
CoV-1, the related beta-coronavirus responsible for the SARS epidemic in 2002 
and 2003.13  
We are also interested in how the E and S proteins from SARS-CoV-2 
affect ENaC function. Ji et al. used electrophysiology to suggest that both SARS-
CoV-1 E and S proteins markedly decreased ENaC activity in Xenopus laevis 
oocytes.14 After pharmacological experiments to probe the cause of this inhibition, 
Ji et al. suggested that the E and S protein decreased ENaC protein levels via a 
protein kinase C (PKC)-dependent mechanism.14 ENaC helps regulate fluid levels 
in the lung, and if this function is inhibited, pulmonary edema can develop.15 
Pulmonary edema has been observed in COVID-19 patients, so inhibition of ENaC 
via E and S protein expression may have been conserved in SARS-CoV-2.16,17 
Other ion channels may be affected by SARS-CoV-2 proteins, so we tested the 
generality of our results by studying how the SARS-CoV-1 and SARS-CoV-2 
proteins affect α3β4 nAChR activity. Finally, we begin mechanistic work to explain 
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how the SARS-CoV-1 and SARS-CoV-2 proteins affect ENaC and α3β4 nAChR 
currents. 
6.3 Results 
6.3.1 SARS-CoV proteins do not form ion channels in the plasma membrane 
Many viruses rely on the function of viroporins, including viruses in the 
coronavirus family.2 ,4,6,18,19 The ORF3a and E protein are postulated to be 
viroporins.20 Furthermore, there are viral protein-protein interactions such that the 
individual protein, do not create a pore, but together they do so.21 Here we find that 
the injection of SARS-CoV-1 S and E and SARS-CoV-2 Nsp2, Nsp3, Nsp4, Nsp6, 
ORF3a, ORF8, M, E, and S protein mRNA, all simultaneously or individually, into 
Xenopus oocytes does not produce conductances in the plasma membrane 
(Figure 6.1).  
 
6.3.2 SARS proteins are expressed following mRNA injection 
Although most properly transcribed mRNA is translated into proteins when 
injected into oocytes, there are exceptions. Here, we made immunoblots to 
determine whether a subset of these SARS proteins are translated in oocytes. We 
specifically studied the S, E, and SARS-CoV-2 ORF8 proteins. Each SARS protein 
was only observed in oocytes injected with their respective mRNA (Figure 6.2). 
These results suggest that S, E, and SARS-CoV-2 ORF8 proteins are expressed 
in the oocytes following mRNA injection; inadequate protein translation or protein 





 6.3.3 SARS-CoV-1 E, SARS-CoV-2 E, and SARS-CoV-2 S proteins decrease 
ENaC currents 
Protein-protein interactions between the virus and host are crucial for viral 
entry, replication, maturation, transport, and secretion. Ji et al. investigated the 
SARS-CoV-1 E and S protein interactions with ENaC.14 Here, we repeated these 
experiments and included the SARS-CoV-2 proteins (Figure 6.3). We use SARS-
CoV-2 ORF8 as a negative control plasmid since ORF8 does not produce  
viroporins in the plasma membrane and is not expected to interact with ENaC.20  
Figure 6.1 SARS-CoV-1 and SARS-CoV-
2 mRNA do not produce conductances in 
the plasma membrane of Xenopus 
oocytes. (A-D), Voltage-clamp traces for 
steps from a holding potential of +10 mV 
to various test potentials between -120 
and +70 mV. (A) “All SARS” (oocytes 
injected with SARS-CoV-1 S, SARS-CoV-
1 E, and SARS-CoV-2 Nsp2, Nsp3, Nsp4, 
Nsp6, ORF3a, ORF8, M, E, and S protein 
mRNA) oocytes in ND96 buffer. (B) “All 
SARS” oocytes in high K+ buffer. (C) 
Uninjected oocytes in ND96 buffer. (D) 
Uninjected oocytes in high K+ buffer. (E) I-
V relationship for all samples with error 
bars representing the S.E.M. N = 12 (All 
SARS in ND 96), 13 (All SARS in High 
K+), 5 (uninjected in ND 96), 11 
(uninjected in High K+), 18 (ORF3a 
ND96), 43 (ORF3a, High K+), 8 (E+M, 
ND96), 8 (E+M, High K+), 37 (Nsp4, 
ND96), 45 (Nsp4, High K+), 15 (E, ND96), 





Compared to  oocytes injected with ORF8, oocytes injected with SARS-CoV-1 E, 
Figure 6.2 SARS proteins are expressed in Xenopus oocytes. (A1) Total protein stain 
for the immunoblot that would be probed with E protein antisera. (A2) Immunoblots 
probed with the E protein antisera. The oocytes in each lane were injected with ENaC 
and the SARS proteins designated at the top of the total protein stain. (B1) Total 
protein stain for the immunoblots that would be probed with anti-ORF8 and anti-spike 
protein. (B2) Immunoblots probed with the antibodies designated at the top of each 
immunoblot. The oocytes in each lane were injected with ENaC and the SARS 








currents, with the 
E  proteins 





find that the 
SARS-CoV-2 E 
protein inhibits 
ENaC more than 
the SARS-CoV-1 
E protein. 
Although Ji et al. 
report that SARS-
CoV-1 S protein 
also decreases  
ENaC current, we 
find that this is 
true compared to 
oocytes injected 
Figure 6.3 Representative voltage-clamp currents. Membrane 
potential was held at +10 mV, then stepped to test potentials 
from -120 mV to +70 mV at 10 mV intervals. (A) buffer. (B) 10 
µM amiloride. (C) subtraction of the amiloride traces from the 
buffer traces, produce the amiloride-sensitive currents and are 
used to determine ENaC currents. (D) I-V relationships for 
oocytes injected with ENaC mRNA and SARS proteins. 
“ORF8” = SARS-CoV-2 ORF 8. “1-E” = SARS-CoV-1 E protein. 
“2-E” = SARS-CoV-2 E protein. “2-S” = SARS-CoV-2 S protein. 
“1-S” = SARS-CoV-1 S protein. “2-E[SF55TV]” refers to the 
chimera-like E protein with the partial PTVYVYSRVKNLNSSR-
V sequence. “2-E[R69EG]” refers to the chimera-like E protein 
with the partial PSFYVYSRVKNLNSSEGV sequence (this 
protein is one amino acid longer than wild-type SARS-CoV-2 E 
protein). The dotted line represents the 95% confidence 
interval. n=18 (ENaC only), 49 (ORF8), 52 (1-S), 51 (2-S), 35 
(1-E), 40 (2-E), 30 (2-E[SF55TV]), and 30 (2-E[R69EG]). 
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only with ENaC, the control Ji et al. used.  However, when the control is oocytes 
co-injected with ORF8, there is no significant difference between oocytes co-
injected with SARS-CoV-1 S or the control mRNA. Altogether, we find that the E 
and S proteins from SARS-CoV-2 have a greater inhibitory effect on ENaC than 
their SARS-CoV-1 counterparts. 
The SARS-CoV-1 and -2 E proteins differ at two sequence regions, 
positions 55-56 and 69-70. We constructed two chimera-like E proteins in which 
either the 55-56 or 69-70 sequences differ, but not both. Proteins with the SARS-
CoV-1 E protein residues at 69-70 are one amino acid longer than proteins with 
the SARS-CoV-2 E protein residues at 69-70 because this sequence is Glu-Gly in 
SARS-CoV-1 and Arg-(∆) in SARS-CoV-2. Like both unmutated E proteins, both 
of these chimera-like proteins markedly decreased ENaC current.  
 
 

















Figure 6.4 Currents induced by 100 µM ACh in oocytes expressing mouse α3β4 and 
SARS mRNA. “ORF8” = SARS-CoV-2 ORF 8. “1-E” = SARS-CoV-1 E protein. “2-E” 
= SARS-CoV-2 E protein. “2-S” = SARS-CoV-2 S protein. “1-S” = SARS-CoV-1 S 
protein. The error bars represent the S.E.M. p-values were calculated from an 




 6.3.4 SARS-CoV-1 and SARS-CoV-2 E proteins inhibit α3β4 nAChR currents  
Next, we were interested in the SARS proteins’ general effect on ion 
channels. We studied the α3β4 nAChR as it is readily expressed in Xenopus 
oocytes and plays a role in several respiratory diseases.22 Once again, we find that 
α3β4 currents are significantly reduced when oocytes are co-injected with either E 
protein (Figure 6.4). However, in contrast to our ENaC experiments, SARS-CoV-
2 S protein does not significantly reduce α3β4 currents.   
 
6.3.5 Inhibition does not occur if the SARS-CoV protein mRNAs are injected 24 h 
after ENaC mRNA 
The individual ENaC subunits must be translated, folded, assembled into 
mature channels, and trafficked to the plasma membrane. ENaC currents are 
observed 24 hours after mRNA injection, suggesting that these steps occur within 
that time. To understand whether the SARS-CoV proteins affect ENaC during 
these steps, we injected ENaC mRNA, and waited 24 hours before injecting the 
SARS-CoV mRNA. We find that if the SARS-CoV mRNA is injected 24 hours after 
the ENaC mRNA, there is no ENaC inhibition (Figure 6.5). 
We interpret the experiment of Figure 6.5 as follows. On the one hand, 
delaying ORF8 injection by 24 h significantly increases ENaC conductance by 2-3 
fold, at V < -30 mV and V > +40 mV. This effect may indicate that ORF8 inhibits 
ENaC expression or function modestly during the first 24 h after co-injection. On 
the other hand, delaying the SARS-CoV-2 S, SARS-CoV-1 E, or SARS-CoV-2 E 
mRNA injection by 24 h produces more dramatic increases. Quantitative 
comparisons are vitiated by the very small currents produced by co-injection; but 
the increase is > 10-fold.  Therefore, we conclude that the severe block of ENaC 
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by SARS-CoV-1 E, SARS-CoV-2 S, or SARS-CoV-2 E proteins all occur at early 
steps in the functional expression of channel proteins. The relatively modest block 
by SARS-CoV-1 S protein presents an intermediate case. Delaying SARS-CoV-1 
S co-injection by 24 h produces a ~ 4-  fold increase in ENaC conductance when 
measured at all voltages outside the -20 mV to + 20 mV range. 
 
 
Figure 6.5 Injecting oocytes with the SARS mRNA 24 hours after ENaC mRNA 
injection does not result in ENaC inhibition. The filled circles represent samples where 
both ENaC and SARS mRNA were injected at the same time. The open circles 
represent samples that had the SARS mRNA injected after the ENaC mRNA. The 
dotted line represents the 95% confidence interval. n = 4 (48h (ENaC + ORF8)), 12 
(48h (ENaC + 1-E)), 13 (48h (ENaC + 2-E)), 8 (48h (ENaC + 1-S)), 11 (48h (ENaC + 
2-S)), 6 (ENaC then ORF8), 8 (ENaC then 1-E), 10 (ENaC then 10), 5 (ENaC then 1-
S), and 6 (ENaC then 2-S).  
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6.3.6 Mutating the furin cleavage site in SARS-CoV-2 S protein improves ENaC 
function 
ENaC function is dependent on a furin cleavage event, while α3β4 does 
not depend on furin cleavage.23 The ability of SARS-CoV-2 S protein to inhibit 
ENaC, but not α3β4, could be explained by the furin cleavage site in SARS-CoV-  
2 S protein that may compete for available furin. Indeed, several others have 
proposed this mechanism for possible ENaC inhibition via SARS-CoV-2 S protein 
expression.24-26 We mutated the 682RRAR685 motif to 682AAAR685 to destroy the furin 
cleavage site. In oocytes expressing ENaC, there was greater current when we 
expressed the SARS-CoV-2 S [682AAAR685] mutant instead of the wild-type SARS-
CoV-2 S protein (Figure 6.6). However, the currents were not completely restored, 
suggesting that other factors influence ENaC inhibition by SARS-CoV-2 S protein.  
 
6.3.7 PKC activation decreases ENaC and α3β4 currents 
PKC helps regulate many cellular functions, including net endocytosis.27 Ji 
et al. suggested that PKC activation is the cause for decreased ENaC currents due 
to SARS-CoV-1 S or E protein expression. They hypothesized that as endocytosis 
occurs, the number of ENaC channels on the plasma membrane decreases, and 
the total ENaC current decreases pari passu. Here, we verify that PKC activation 
decreases ENaC and α3β4 currents after a 15-minute treatment in 10 µM PMA, a 
PKC activator.28 We find that compared to vehicle, currents are significantly lower 
after PMA treatment, consistent with Ji et al.’s hypothesis that PKC activation 
decreases plasma membrane currents (Figure 6.7). Additionally, based on our 
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capacitance measurements, net endocytosis increased (membrane area 
decreased ~5%) following PMA treatment (Figure 6.8).  
 6.3.8 PKC inhibition does not abolish SARS-CoV-1 E, SARS-CoV-2 E, or SARS-
CoV-2 S protein-induced reductions in ENaC currents 
We tried to inhibit PKC activation with Gö-6976, a known PKC inhibitor.29 
We hypothesized that if we can prevent PKC activation with Gö-6976, then the 
effects of SARS-CoV-1 E, SARS-CoV-2 S, and SARS-CoV-2 E will be abolished. 
However, after incubating oocytes in 1 µM Gö-6976 following mRNA injection, we 
found no differences between Gö-6976-treated and vehicle-treated cells (Figure  

















Figure 6.6 Mutating the SARS-CoV-2 S protein furin cleavage site (682RRAR685) to 
682AAAR685 improves ENaC function after coinjection. The dotted line represents the 





Figure 6.7 PKC activation via 10 µM PMA treatment decreases ENaC and α3β4 
currents. Oocyte currents were measured before (Pre-) and after (Post-) a 15-minute 
treatment with vehicle or 10 µM PMA. (A) Traces for oocytes expressing ENaC. Red 
traces represent before PMA (“Pre-PMA”) and the black traces are after PMA (“Post-
PMA”). This oocyte showed unusually large suppression of ENaC currents by PMA 
(B) I-V relationships for oocytes expressing ENaC before or after vehicle or PMA 
treatment. The dotted line represents the 95% confidence interval. n = 10 (Pre-Veh), 
10 (Post-Veh), 12 (Pre-PMA), 13 (Post-PMA). (C) Traces for oocytes expressing 
α3β4; 100 µM ACh was present as noted by the horizontal bar. Red traces represent 




6.9). Once again, this is somewhat consistent with Ji et al.’s data in that Gö-6976 
treatment did not completely recover ENaC currents, although our data suggest a 
much less impressive improvement with Gö-6976 treatment. Nonetheless, both Ji 
et al. and we suggest that although PKC activation can decrease ENaC currents, 
the SARS proteins appear to be utilizing other mechanisms as well. 
  
 6.4 Discussion 
COVID-19 has wreaked havoc on the world in unprecedented ways. We 
show that the SARS-CoV-1 and SARS-CoV-2 proteins, expressed either singly or 
in combination, do not produce conductance at the plasma membrane (Figure 
6.1). This contrasts with reports suggesting that SARS-CoV-1 and SARS-CoV-2 
may produce viroporins on the plasma membrane.30-32 We verify that proteins are 
being translated by detecting E, S, and ORF8 proteins via immunoblots (Figure 
6.2) and by observing inhibition of other channels. Whereas these results do not 
Figure 6.8 PKC activation via PMA treatment decreases membrane 
capacitance. The error bars represent the S.E.M. p-values were 
calculated from an unpaired t-test where *** denotes p < 0.001.  
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prove the absence of ion channels in other intracellular regions, the plasma 
membrane’s lack of ion channels complicates some therapeutic strategies.5  
 Caveats include that a Xenopus oocytes differ markedly from human 
epithelial cells, so further work must be done on other model systems to produce 
a more comprehensive understanding of SARS-CoV-2 proteins’ roles in COVID-
Figure 6.9 PKC inhibition with 1 µM Gö-6976 does not prevent E protein or SARS-
CoV-2 S protein-related decreases in ENaC activity. For each coinjection, there is no 
significant difference between the oocytes treated with vehicle or Gö-6976. “ORF8” = 
SARS-CoV-2 ORF8, “1-E” = SARS-CoV-1 E protein. “2-E” = SARS-CoV-2 E protein. 
“2-S” = SARS-CoV-2 S protein. Error bars represent S.E.M. The dotted line 
represents the 95% confidence interval. n = 11 (ORF Veh), 11 (1-E Veh), 12 (2-E 
Veh), 10 (2-S Veh), 14 (ORF8 + Gö-6976), 13 (1-E + Gö-6976), 7 (2-E + Gö-6976), 
and 11 (2-S + Gö-6976). 
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19. Also, the intracellular life cycle of a coronavirus involves several steps in  
organelles; if the SAR-CoV proteins produce channels in organelles, these might 
not traffic to the plasma membrane and might therefore escape detection in our 
experiments. 
As in many viral diseases, viral protein-host protein interactions underlie 
the pathophysiology of COVID-19. Therefore, we have studied interactions that 
include the effects of E or S protein expression on ENaC or α3β4 activity. In SARS-
CoV-1, Ji et al. found that E and S protein expression decreased ENaC activity.14 
Our observations suggest that the inhibitory properties are greater for the SARS-
CoV-2 E protein and S protein (Figure 6.3). We found that in α3β4-expressing 
oocytes, both E proteins decreased α3β4 currents (Figure 6.4). For S protein, Ji 
et al. found that SARS-CoV-1 S protein decreased ENaC activity.14 In contrast, our 
results suggest that SARS-CoV-2 S protein, but not SARS-CoV-1 S protein, has 
this effect. This difference is likely due to a difference in our control experiments. 
On the one hand, Ji et al. compared their currents to samples only injected with 
ENaC; on the other hand, we compared our results to samples co-injected with 
ORF8, a protein that is not expected to interact with ENaC. Therefore, we 
hypothesize that the decreased ENaC currents that we observe for SARS-CoV-1 
S protein (that do not significantly differ from samples injected with ORF8) are due 
to occlusion of translational or trafficking pathways instead of a selective effect 
from the translated proteins.33 However, oocytes co-injected with SARS-CoV-2 S 
protein did have significantly lower ENaC currents compared to our controls. We 
show that the inhibitions do not occur if the SARS-CoV protein mRNAs are injected 
24 h after ENaC mRNAs, suggesting that SARS-CoV proteins affect early step(s) 
in the functional expression of channel proteins (Figure 6.5).  
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Previous studies show that some viral fusion proteins are activated by 
proteolysis.34 The increased inhibition with SARS-CoV-2 S protein is consistent 
with the appearance of a furin cleavage site.35 This site is identical to the furin 
cleavage site in the ENaC-α subunit, so SARS-CoV-2 S protein may be competing 
for available furin, thereby decreasing the proteolytic activation of ENaC-α and 
thus decreasing ENaC activity.26,36,37 SARS-CoV-2 S protein competing for furin 
would also explain how α3β4 currents do not change with SARS-CoV-2 S protein 
expression: α3β4 does not depend on furin cleavage for activity. Our experiments 
with the SARS-CoV-2 S [682AAAR685] mutant support this hypothesis, although it 
does not completely explain SARS-CoV-2-induced ENaC inhibition as uninhibited 
ENaC currents were not observed. (Figure 6.6). 
We hypothesized, similarly to Ji et al., that PKC activation may partly 
underlie the decreased currents.14 When PKC is activated, net endocytosis 
increases.27 Decreasing the number of channels on the membrane via endocytosis 
is expected to decrease currents. When we examined this relationship 
quantitatively in oocytes treated with PMA, we observed only a modest (~5%) 
decrease in membrane area (as a decrease in capacitance) along with a much 
larger decrease in membrane currents through ENaC and α3β4 (Figure 6.7 and 
Figure 6.8). Furthermore, when we blocked PKC activation with Gö-6976 
treatment, we did not block the inhibitory effects of SARS-CoV-1 E, SARS-CoV-2 
E, or SARS-CoV-2 S proteins (Figure 6.9). While these SARS proteins may be 
activating PKC, there appear to be other mechanisms that inhibit ENaC activity as 
well. 
Both chimera-like E protein constructs suppressed ENaC currents like the 
parent proteins. Although we could not directly probe events in the Golgi (where 
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the E protein is expected to localize)38, this result suggests that combining the two 
regions conferred no selective advantage to SARS-CoV-2, at least as measured 
by our assay of ENaC suppression. Among the presently known SARS-CoV-2 
variant lineages, we have noted no mutations at the 55-56 and 69-70 positions. 
Several members of the B.1.351 lineage have a P71L mutation; this position is 
near the 69-70 sequence and immediately upstream from a candidate PDZ domain 
binding motif at the C-terminus.      
6.5 Conclusion 
Unfortunately, COVID-19 will not be the last virus to cross over into humans 
and strain public health resources. While the COVID-19 vaccine will greatly help 
the world recover from this pandemic, basic research into SARS-CoV-2 will 
improve our response when the next viral infection emerges.  
Because SARS and COVID-19 are different diseases, one expects to note 
differences between the proteins from SARS-CoV-1 and SARS-CoV-2. Here, we 
show that the E and S proteins inhibit ENaC and are more potent at inhibiting ENaC 
than their SARS-CoV-1 counterparts. ENaC participates in lung fluid homeostasis, 
so an improperly functioning ENaC may result in pulmonary edema.14,15 If ENaC is 
inhibited more in COVID-19 than in SARS, this may help us predict the course of 
future viral diseases. Indeed, if pulmonary edema is more prominent in COVID-19 
patients than SARS patients, the different S and E proteins may be responsible. 
Additionally, the SARS-CoV-2 variants are troubling. Most researchers emphasize 
that any differential virulence or lethality of variant S proteins may arise via 
differential interactions with antibodies—induced either by host infection or by 
vaccines. This report presents quantitative data on another S protein effect: 
consequences of interactions with host non-antibody proteins. One such 
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interaction, not studied here, is binding to the ACE2 receptor. Measuring the 
interactions made by the S and E proteins with human proteins may be crucial to 
understanding COVID-19 and the SARS-CoV-2 variants. We are still in the early 
stages of understanding SARS-CoV-2 and COVID-19. Although our findings may 
be meaningful and important, they represent only part of the required knowledge 
about SARS-CoV-2 and COVID-19. 
6.6 Materials and Methods 
6.6.1 cDNA and mRNA  
Human ENaC subunit cDNAs h-alpha-ENaC, h-beta-ENaC, and h-gamma-




IRES-Puro were gifts from Nevan Krogan.7 pDONR223 SARS-CoV-2 NSP6 and 
pDONR207 SARS-CoV-2 NSP3 were gifts from Fritz Roth. pUC57-2019-nCoV-S 
plasmid was purchased from MolecularCloud. pcDNA3.1-SARS-Spike was a gift 
from Fang Li.39 The SARS-CoV-2 E protein plasmid was constructed and 
packaged by VectorBuilder. The vector ID, VB200324-4348fzb, provides 
information about the vector on vectorbuilder.com. SARS-CoV-1 E protein was 
produced by introducing point mutations in the SARS-CoV-2 E protein plasmid. All 
SARS-CoV-1 and SARS-CoV-2 proteins were cloned into the pGEMHE vector for 
optimal Xenopus oocyte expression. The mouse α3 and β4 nicotinic acetylcholine 
receptor mRNAs have been described previously.40 mRNA was produced using 
the mMessage mMachine T7 transcription kit (Invitrogen) and purified with the 
RNeasy Mini Kit (Qiagen).  
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6.6.2 Protein expression in oocytes 
Xenopus laevis stage V and VI oocytes were harvested via standard 
protocols.41 For each ENaC subunit, 12 ng of mRNA was injected into oocytes. For 
mouse α3β4 nAChR expression, 10 ng of mRNA for each subunit were injected 
into each oocyte. For the SARS-CoV-1 or SARS-CoV-2 proteins, 20 ng of mRNA 
were injected into oocytes along with the ENaC or α3β4 nAChR mRNA. For 
oocytes injected with a single SARS-CoV-2 protein mRNA, each oocyte received 
20 ng of mRNA. For oocytes injected with nine SARS-CoV-2 and two SARS-CoV-
1 protein mRNAs, 3 ng of each were injected into each oocyte. The final mRNA 
injection took place 24 hours before electrophysiological recording or 48 hours 
before lysis for immunoblotting.  
 
6.6.3 Immunoblotting 
48 hours post-injection, oocyte lysates were prepared by lysing oocytes 
osmotically in a 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), pH 7.3 solution (20 µL per oocyte).42 Lysates were centrifuged for 5 
minutes at 10,000 rpm. The supernatant was used to probe for E protein. The 
pellets were resuspended in 50 mM Tris, 150 mM NaCl, 1% NP-40, pH 7.3 buffer, 
and these solutions were used to probe for ORF8 and S protein. 12% Mini-
PROTEAN® TGX™ Precast Protein Gels (Bio-Rad) were used for electrophoresis 
and wet-transferred onto an Immun-Blot® LF PVDF membrane (Bio-Rad). E 
protein was probed using rabbit antiserum that responds to the C-terminus of 
SARS-CoV-1 E protein at 1:1000 concentration. The antiserum was a gift from 
Carolyn Machamer.18 The ORF8 was probed using a primary antibody at 1:500 
concentration (GeneTex, Cat#: GTX135591). S protein was probed using a 
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primary antibody at 1:500 concentration (Invitrogen, Cat#: PA581795). The 
primary antibodies were visualized using IRDye® 800 CW donkey anti-rabbit 
antibody (Li-Cor, Cat#: 926-32213) at 1:1000 concentration.  
6.6.4 Electrophysiology 
Oocyte recordings were performed in two-electrode voltage-clamp mode 
using the OpusXpress 6000A instrument (Axon Instruments). Oocyte equilibration 
and washes were performed with ND96 [96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 
1 mM MgCl2, and 5 mM HEPES (pH 7.4)] or High K+ buffer [2 mM NaCl, 96 mM 
KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES (pH 7.4)]. Microelectrodes 
were fabricated from borosilicate glass (BF150-117-15, Sutter Instrument 
Company, Novato, CA) using a one-stage horizontal pull (P-87, Sutter Instrument 
Co., Novato, CA) and filled with 3 M KCl. Pipette resistances ranged from 0.3 to 
3.0 MΩ. The initial holding potential was +10 mV for ENaC expressing oocytes or 
-60 mV for α3β4 expressing oocytes. For ENaC expressing oocytes, voltages were 
sampled from -120 mV to +70 mV at 10 mV intervals and the currents through the 
oocyte membrane were recorded. For α3β4 expressing oocytes, the potential was 
held at -60 mV throughout the experiment, and the currents were measured during 
100 µM acetylcholine (ACh) application. Data were sampled at 50 Hz. Traces were 
processed in Clampfit 11.1. In ENaC expressing oocytes, amiloride-sensitive 
currents were calculated by subtracting currents measured in the presence of 10 
µM amiloride (an ENaC inhibitor) from the average currents measured in ND96 
taken before amiloride treatment and after amiloride wash-out. For PMA 
experiments, oocyte currents were measured before and after 15 minute 
incubation in the vehicle or 10 µM PMA. For Gö-6976 experiments, the oocytes 
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were incubated in 1 µM Gö-6976 right after injection until electrophysiology 
experiments were performed. 
Analysis and curve fitting was performed using Prism (GraphPad Software, 
La Jolla, CA). For the ENaC experiments in Figures 6.3, 6.5, 6.6, 6.7, and 6.8, we 
fitted a second-order polynomial to each current-voltage dataset (> 10 oocytes, 
except where noted), to account for the nonlinear ENaC conductance. For control 
currents (for instance, co-injection with ORF8), the reversal potential (V0) varied < 
5 mV within each experiment; however, the much smaller currents resulting from 
co-injection of other SARS-Cov-1 and SARS-CoV-2 proteins vitiated a meaningful 
estimate of V0.  The data plots show the 95% confidence limits of these fitting 
functions at each voltage between -120 mV and +70 mV. “Significant differences” 
between current-voltage relations in a particular voltage range mean that the 95% 
confidence limits do not overlap in that voltage range.  This presentation has the 
physiological and pathophysiological relevance (a) that ENaC is expressed 
primarily in epithelial cells—a likely site of SARS-Cov-2 infection and 
proliferation43-45 and (b) where possible, we extend the analysis to the > -60 mV 
resting potentials typical of epithelial cells.  
Membrane capacitance was measured on oocytes for each voltage jump. 
The capacitive charge ∆Q was calculated by temporally integrating the transient 
capacitive current (∆Q  = ∫∆I) during the 20 ms following the command voltage 
jump. Figures 6.3A and 6.3C show how relatively large conductive currents 
challenge the voltage-clamp circuitry, the current amplifier’s compliance, and the 
linearity of the current electrode so that ∆Q becomes distorted by the presence of 
a large conductance. An example of the resulting artifact is our lab’s erroneous 
overestimate of the decreases in oocyte capacitance that accompany large 
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decreases in K+ currents.46 To minimize such artifacts in the present experiments, 
we measured capacitance during the blockade of most ENaC currents by amiloride 
(10 mM). We also subtracted remaining time-independent conductive currents by 
extrapolating such currents back to the time of the jump in the command voltage. 
We verified that the capacitive transient ∆Q showed a linear dependence on the 
voltage jump ∆V, allowing us to measure C = ∆V/∆Q.  
In analyses of data that emphasized currents at a single potential, an 
unpaired t-test was used to determine statistical significance between results with 
ORF8 coinjection vs each other coinjection (Figure 6.4). A p-value of 0.05 or less 
was considered to be statistically significant. 
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Appendix 1: Investigating protein-protein interactions in 
the estrogen receptor α with photocrosslinking amino 
acids 
This work was done in collaboration with Dr. Matthew Rienzo, Dr. Richard 
Mosesso, and Gabrielle Tender 
A1.1 Abstract 
 The estrogen receptor α (ERα) is one of the most investigated proteins due 
to its role in breast cancer. ERα is a nuclear transcription factor whose function is 
dependent on hormones and several protein-protein interactions (PPIs). Many of 
these PPI studies used mass spectrometry and immunoblot experiments that 
relied on maintaining non-covalent interactions between the proteins. 
Unfortunately, these methods would miss some of the transient or weak PPIs that 
might not survive some of the harsh conditions utilized in mass spectrometry and 
immunoblots. Here, we incorporate a photocrosslinking amino acid, 
azidophenylalanine (N3Phe), to help capture these weak or transient PPIs. We first 
investigated the dimerization event required for ERα activation as a proof-of-
concept of our technique. We incorporated N3Phe in the dimerization interface and 
observed an increase in dimerization with increasing concentration of the ERα 
agonist, estradiol (E2). Next, we attempted to observe a decrease in dimerization 
with ERα antagonists, tamoxifen and fulvestrant. Surprisingly, both of these 
antagonists induced dimerization, demonstrating that these antagonists are not 
inhibiting dimerization. Finally, we moved the N3Phe to the hinge region of the ERα 
to look for non-dimer PPIs. We found that the ERα will interact with some unknown 
protein when the N3Phe is incorporated at residue 275. Despite our best attempts 
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to identify the unknown protein partner, we could never get enough protein to get 
a definitive identification via protein gel or mass spectrometry. We attempted stable 
isotope labeling using amino acids in cell culture (SILAC), but it did not give 
satisfactory results. 
A1.2 Introduction 
 Nuclear transcription factors are vital to a cell's development as they are 
responsible for turning certain genes on and off. Many of these transcription factors 
are controlled by hormones. Proper function of both the hormones and 
transcription factors is critical to the health of the organism. One example of how 
a malfunctioning transcription factor can lead to disastrous results is ERα's role in 
breast cancer. Breast cancer is the most common form of cancer in women, 
affecting approximately one in eight women in the United States.1 Due to the 
prevalence of breast cancer, some of the biggest drugs on the market target ERα. 
The prime example is tamoxifen, which has made billions of dollars and saved 
many lives for over two decades.2 
 ERα has several regions that depend on conformational changes to occur 
for action as a transcription factor.3 The major components are the ligand-binding 
domain (LBD), the DNA-binding domain (DBD), and a hinge domain between the 
LBD and DBD (Figure A1.1).4,5 The LBD includes the dimerization interface and 
is the binding site for most agonists and antagonists. Following ligand binding, 
several conformation changes occur that "cap" the ligand-binding site, induce 
dimerization, and cause dissociation from its chaperone proteins.6,7 Activation may 
cause ERα to bind to estrogen response elements (EREs) as a dimer in the 
nucleus and induce transcription at nearby DNA sequences. Alternatively, ERα 
may bind to other transcription factors after activation to promote transcription. In 
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addition to activation, dimerization, and binding to EREs or transcription factors, 
several factors will affect ERα function.8 For example, tamoxifen, which is great at 
stopping breast cancer cell 
growth, can increase one's 
risk of endometrial cancer 
because tamoxifen is an 
ERα antagonist in breast 
tissue but an agonist in 
bone and uterus tissue.8 
 Many of these 
questions involve the 
hinge region. The hinge 
region is a largely 
disordered region between 
the DBD and the LBD that 
is important for relaying the 
effects of the LBD to the 
DBD and is responsible for 
some of the differences 
between ERα and 
estrogen receptor β (ERβ).9 The hinge region is also responsible for coordinating 
the actions of the two activation functions, AF-1 and AF-2, whose synergy is 
greater in ERα than ERβ.9 Furthermore, the hinge region is the location of some 
important phosphorylation and PPI sites in addition to the nuclear localization 
sequence.10 Nevertheless, partly due to the lack of structural information, our 
Figure A1.1 Structures of the ERα. (A) The DNA 
binding domain (PDB: 1HCQ) and (B) the ligand 
binding domain. The green helicies respresent the 







understanding of the hinge region and the location of some of the PPI interfaces 
is lacking. 
 Here, we go in a new direction to investigate ERα PPIs using a 
photocrosslinking amino acid, N3Phe, to precisely determine where certain PPIs 
occur. N3Phe is a non-canonical amino acid (NCAA) that, after UV irradiation, will 
generate a nitrene that will capture transient PPIs (Figure A1.2). These 
interactions may break during standard immunoblot or mass spectrometry and 
may therefore go undetected. Since we will be capturing these interactions with a 
covalent bond, we can observe these PPIs using the harsh conditions inherent in 
protein gels and mass spectrometry. First, we start observing homodimerization 
and only observe a dimer band if we incorporate N3Phe, activate ERα, and irradiate 
the cells with UV light, thus providing a proof-of-concept for our PPI assay. Next, 
we moved to several sites in the hinge region. We found a novel, non-dimer band 
when we incorporated N3Phe at either residue 265 or 275. In order to identify the 
protein binding to the ERα hinge region, we attempted SILAC mass spectrometry 
and were unsuccessful. Unfortunately, crosslinked protein yields were insufficient 








A1.3 Results and Discussion  
A1.3.1 Incorporating N3Phe into functional ERα 
 As mentioned in the introduction of this thesis, NCAAs can be incorporated 
into proteins by providing the system with an orthogonal tRNA that will recognize 
a stop codon and an orthogonal synthetase to charge the tRNA with the desired 
NCAA.11 However, there are instances (similar to the difficulties detailed in Chapter 
2) where regions of proteins will not accept NCAAs, or the protein will cease to 
function with certain mutations. Since N3Phe is an aromatic amino acid and we 
wished to probe the dimerization interface, we decided to test His516. His516 is 
on helix 12 on ERα, which spans the dimerization interface (Figure A1.1). To 
incorporate N3Phe at the 516 residue, we mutated this codon to TAG so that our 
orthogonal synthetase could incorporate N3Phe at this position.12 
 To verify that our mutated ERα was functional, we also expressed a 
luciferase protein that depended on ERα binding to an ERE on the luciferase vector 
for expression. In experiments where we tranfected wild-type ERα, luciferase 
intensity was directly related to the amount of ERα plasmid used (Figure A1.3A). 
In cells transfected with ERα[His516TAG], we found that cells treated with media 
Figure A1.3 Verifying the presence of functional ERα. (A) Intensity from the luciferase 
assay is directly dependent on the amount of ERα transfected into the HEK193T cells. In 
this assay, wild-type ERα was used. (B) When cells are transfected with ERα[H516TAG] 
and the N3Phe tRNA/synthetase, the presence of N3Phe in the cell media significantly 
increases ERα activity. (C) In cells treated with N3Phe and transfected with 
ERα[H516TAG], there is a dependence on also transfecting the N3Phe tRNA and 
synthetase. P-values are calculated from a Student’s t test. ****, p < 0.0001 
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spiked with N3Phe had greater intensity than those not supplied with the NCAA 
(Figure A1.3B). Finally, we found significantly greater chemiluminescence from 
cells transfected with ERα[His516TAG] and the N3Phe tRNA/synthetase over 
those not transfected with the tRNA/synthetase (Figure A1.3C). We note that the 
luciferase measurements were orders-of-magnitude higher with the wild-type ERα 
than the N3Phe incorporated ERα. This suggests that NCAA incorporation is rather 
inefficient. 
A1.3.2 Observing ERα dimer bands in protein gels following photocrosslinking 
 After determining that we were able to generate functional ERα with N3Phe, 
we decided to move into crosslinking assays, more specifically, using protein gels 
to detect higher molecular weight species of ERα (i.e., dimers). We used a vector 
encoded for ERα[His516TAG] with a green fluorescent protein (GFP) at its N-
terminal. We decided to attach GFP at the N-terminal to understand how much 

































Figure A1.4 Dimerization increases with increasing concentrations of E2. 
HEK293T cells were transfected with ERα[His516TAG] and the N3Phe 
tRNA/synthetase. 24 hours after transfection, 10 nM E2 was added. 24 hours post 
E2 addition, cells were irradiated with 365 nm light to induce crosslinking, lysed, and 
ran on a protein gel. Bands were detected by exciting and capturing GFP 
fluorescence. (A) Representative protein gel demonstrating that dimerization (as 
represented by the 150 kDa band) increases with increasing concentrations of E2. 





protein got truncated at the TAG codon and see the dimers without immune 
reagents. We continued with our preliminary experiments by looking at the 
dependence on the [E2] for dimerization (Figure A1.4). One major concern going 
into these experiments was how GFP would behave in the gel and if we could 
quantify the data. Fortunately, the data from our assay was consistent with 
literature precedence.13-15  
A1.3.3 Tamoxifen and fulvestrant induce dimerization 
 There have been hypotheses that some of the ERα antagonists inhibit 
activation by preventing dimerization.19 Alternately, these ligands may induce 
dimerization and inhibit ERα's transcriptional activity in other ways.3,20,21 Here, we 
decided to use our assay on two of the most popular ERα antagonists, tamoxifen 
and fulvestrant. 
 First, we ensured that both antagonists prevent ERα activation via a 
luciferase assay (Figure A1.5). Both antagonists decreased ERα activity, 
consistent with what we expected to see from these drugs. Next, we decided to 
put both fulvestrant and tamoxifen through our dimerization assay. Interestingly, 
we see dimer bands from samples treated with either tamoxifen or fulvestrant 
(Figure A1.6). Both of these results suggest that some downstream step is 
Figure A1.5 Luciferase activity assays demonstrating that both (A) tamoxifen and (B) 
fulvestrant (ICI) inhibit ERα. HEK293T cells were transfected with ERα and a luciferase 
plasmid whose expression is dependent on ERα activity. P-values were calculated from 
an unpaired Student’s t-test. **, p = 0.001 
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inhibited following dimerization. This conclusion is consistent with what others 
have found regarding activation or inactivation mediated by these antagonists. 
Arao et al. found that a mutation in the C-terminal region (outside the dimerization 
helix) would change fulvestrant and tamoxifen into agonists.22 Dimerization via 
tamoxifen or fulvestrant has been observed before in bioluminescence resonance 
energy transfer (BRET) experiments.24 Altogether, we find that both agonists and 
antagonists are capable of inducing ERα dimerization. 
A1.3.4 Observing a non-dimer PPI in the ERα hinge region 
 Following the proof-of-concept experiments demonstrating that we can 
covalently capture PPIs with N3Phe, we decided to move the N3Phe incorporation 
site to the hinge region. Compared to the DBD and the LDB, the hinge region has 
garnered less attention, but it is still worthy of investigation.9,16-18 The hinge region 
consists of residues between 255-305, and at the moment, there are no complete 
structures of this region. We tested four different sites within the hinge region and 
observed PPIs when we incorporated N3Phe at residues 265 or 275 (Figure A1.7). 
We decided to go through with the 275 site since it was closer to the middle of the 
Figure A1.6 Both tamoxifen and fulvestrant induce dimerization.  
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hinge region. These protein gels were reproducible, suggesting that this is a real 
PPI. 
 We next decided to investigate whether this PPI was a dimerization event. 
Although the molecular weight of the hinge region PPI would suggest that it is 
binding to something heavier than ERα, we needed to validate this inference. We 
decided to generate two ERα plasmids: a GFP-ERα with no TAG mutations and 
ERα[E275TAG] without GFP (Figure A1.8). Under these conditions, we should be 
able to observe dimerization, but not a non-dimer PPI. Compared to experiments 
using GFP-ERα[E275TAG], we do not see the same higher molecular weight band 




265     275     286       296 
Figure A1.7 PPIs observed by crosslinking 
certain residues in the hinge region. We 
incorporated N3Phe at residues 265, 275, 285, 
and 296. We observed bands with N3Phe at 265 
and 275 that are slightly above where we observe 




A1.3.5 Attempts to identify hinge region PPI using mass spectrometry and 
immunoblots 
 Traditionally, the proteins within a PPI are identified by mass spectrometry, 
and then their identities are validated via immunoblots. We attempted to use a 
similar workflow to generate promising candidates via mass spectrometry and test 
them using immunoblots. 
 Our initial attempts extended the experiments depicted in Figure A1.7 by 
performing an in-gel digest of the bands with the crosslinked ERα. Unfortunately, 
due to the nature of NCAA mutagenesis and photocrosslinking, the yields from 
these bands were quite low, and a confident detection could not be made. Even 
the ERα was fairly low compared to the other proteins identified by mass 
spectrometry. A 
major issue is that 
there was no 
enrichment, so the 
gel band contained 
everything in the 
cell that migrated 





utilized SILAC to 
help improve the 
Figure A1.8 The PPI in the 
hinge region is not a dimer. 
(A) Scheme for detecting 
whether the higher molecular 
weight band is a dimer or not. 
Under these conditions, the 
only higher molecular weight 
band would be a dimer. A 
non-dimer PPI would not 
fluoresce. (B) The left lane is 
using the conditions 
described in (A), and we see 
no higher molecular weight 
band. The right lane uses the 
plasmid with both GFP and 











signal-to-noise ratio. In 
unlabeled experiments, 
we had no way to know 
what proteins were 
"background" and 
which could be targets 
due to the low 
concentrations of the 
proteins in the band. 25 
One can run controls, 
but this requires cutting 
another band, and it is 
nearly impossible to 
perfectly repeat the gel electrophoresis (protein migration will differ from lane to 
lane) and the gel cutting. In SILAC experiments, one sample is grown in "heavy" 
media, which contains some amino acids made with 15N and 13C (Figure A1.9). 
Since these amino acids will contain heavier proteins, the peptides detected in the 
mass spectrometer can be differentiated from the peptides produced from cells 
incubated in standard media. We utilize this technique in order to use one lane for 
both the experimental and the control samples. SILAC experiments will allow us to 
have perfect replication between the gel electrophoresis and gel cutting steps with 
both the experimental and control sample.  
We were able to get strong incorporation of the heavy amino acids into our 
experimental samples (>98% of proteins had heavy amino acids), but it did not 
significantly improve our ability to identify hits. One small exception was the heat 
Figure A1.9 Brief summary of SILAC protocol to 




shock protein 90 (Hsp90), which consistently showed up in our experimental 
samples. We were further encouraged to evaluate Hsp90 because Hsp90 is a 
chaperone for ERα.26,27 Unfortunately, when we probed a protein blot with anti-
Hsp90, we only observed a band corresponding to the Hsp90 monomer, 
suggesting that the antibodies worked and the ERα[E275TAG] PPI partner was 
not Hsp90. 
A1.4 Conclusion 
 We made some strides in developing a new dimerization assay that is not 
directly dependent on mass spectrometry, immunoblots, or resonance energy 
transfer assays. The innovation in our approach is that we know the product of the 
photocrosslinking by selectively placing the N3Phe in a place where only 
dimerization can occur. Indeed, we only observed dimerization as the major bands 
we could identity were the truncated ERα, full-length ERα, and dimerized ERα. We 
envision that this strategy could be applied to many other dimerization events since 
dimerization is a common step in various activation mechanisms. 
 We could also do more conventional photocrosslinking experiments where 
we discovered a potentially unknown PPI in the ERα hinge region. Unfortunately, 
the concentration of the crosslinked product was insufficient for definitive 
identification of the protein partner, even in our SILAC experiments. Future efforts 
will probably go into a different biological system where protein yields can be 
greater. Precedence suggests moving into bacteria for these experiments to get 
significantly more protein since bacteria is easier to grow than human cells. 
Alternately, we could attempt other enrichment strategies. We briefly attempted to 
use a 6xHis tag to selectively pull-down ERα, but our purification was 
unsatisfactory. This is again likely a result of poor protein yields. Lastly, we can 
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move to another protein that has behaved better in photocrosslinking experiments. 
We believe that identifying PPIs via photocrosslinking NCAAs is an interesting and 
precise method that we hope to use in the future. 
A1.5 Materials and Methods 
A1.5.1 Transfection and protein gels 
 
eGFP-ERα was expressed in pcDNA3.1(+), and mutations were 
accomplished via QuikChange (Stratagene). The orthogonal aminoacyl-tRNA 
synthetase/tRNA pair was encoded in a pU6 plasmid (a gift from Professor 
Michelle Krogsgaard). Transfections were conducted when cells were 50% 
confluent in a 35 mm-petri dish using 3 μL Xfect polymer(Takara), 7.5 ng ERα 
plasmid, 2.5 ng synthetase plasmid, and Xfect buffer up to 100 μL in 1 mL DMEM 
media (with 10% FBS, 100 U/mL penicillin and 100 U/mL streptomycin). Three 
hours after the addition of the Xfect solution, the media was replaced with 3 mL 
DMEM (with 10% FBS, 100 U/mL penicillin, 100 U/mL streptomycin) and 0.5 mM 
N3Phe. Cells were incubated for 24 hours before the addition of E2 and were 
incubated for another 24 hours. Next, the media was replaced with media that did 
not contain N3Phe, and the plates were subjected to a 365 nm LED illumination 
rated for 1 W for 20 min. The media was then removed, and the cells were lysed 
with 1% SDS or Luciferase Lysis Buffer (Promega) and sonicated. These cell 
lysates were then used without purification on MiniProtean TGX Any kD PAGE 
precast gels (Bio-Rad). Gels were run for 1 hour at 150 V and then imaged on a 
Typhoon FLA 9000 (General Electric) with 473 nm laser excitation and an LPB 





A1.5.2 Mass spectrometry 
 After visualizing the desired band on a protein gel, the band was cut from 
the gel. The proteins were reduced by incubating the gel piece in 10 mM 
dithiothreitol (DTT) in 100 mM ammonium bicarbonate for 30 minutes at 50 °C. 
The reducing solution was then removed, and the proteins were alkylated by 
incubating the gel piece in 55 mM iodoacetamide in 100 mM ammonium 
bicarbonate for twenty minutes in the dark. The alkylating solution was then 
removed. The gel piece was dehydrated by washing the gel in 50 mM ammonium 
bicarbonate and then with acetonitrile until the gel piece became opaque white. 
The gel piece was further evaporated under vacuum for 3 minutes. Next, the 
proteins were digested with a 6 ng/µL trypsin solution. The gel piece was incubated 
in this solution for 20 minutes before the excess solution was removed, and the 
gel piece was kept in a minimal volume of 50 mM ammonium bicarbonate to digest 
overnight at 37 °C. The supernatant was collected and the peptides were further 
extracted by adding, then removing, 1% formic acid/2% acetonitrile, 1:1 
acetonitrile/water, and then 1% formic acid in acetonitrile. The pooled extracted 
peptides were dried under vacuum and desalted using a ZipTip® (MilliporeSigma). 
Samples were run on an OrbiTrap Elite (Thermo).  
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